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ABSTRACT 
 
 Over the past few years, researchers have focused their attention on the development of 
targeted cancer therapies to minimize the side effects associated with non-targeted treatments 
such as chemotherapy. Specifically, these approaches have focused on blocking growth factor 
receptors (GFR) that are overexpressed in cancer cells. In this thesis, we also focus on targeting 
overexpressed GFR; however, instead of blocking the GFR, our novel approach aims at using 
them to selectively enhance the endocytotic process of macropinocytosis to deliver peptides that 
either disrupts the mitochondria or inhibits glycolysis.  
 Herein, we show the selective enhancement of macropinocytosis by the fusion protein 
comprised of the keratinocyte growth factor (KGF) fused to elastin like polypeptide (ELP), 
KGF-ELP. Furthermore, we report the synthesis of the fusion protein consisting of 
mitochondriotoxic peptide (KLAKLAK)2 with ELP, (KLAKLAK)2-ELP. We show that 
(KLAKLAK)2-ELP forms nanoparticles (NPs) that are internalized via macropinocytosis and 
their internalization is facilitated by the interaction between the ELP domain and heparan sulfate 
proteoglycan (HSPG) on the cell surface. This internalization results in mitochondrial swelling, 
depolarization and subsequent cell death. Moreover, we show that heterogeneous NPs 
comprising of the two fusions KGF-ELP and (KLAKLAK)2-ELP selectively kill lung cancer 
cells expressing the keratinocyte growth factor receptor (KGFR).  
 We also report the synthesis of the fusion consisting of peptides derived from a 
phosphorylated domain of the glycolytic enzyme phophoglycerate mutase (PGM) and ELP, 
 ix 
PGM-ELP. We demonstrate that this fusion inhibits the step in glycolysis that converts 3-
phosphoglycerate (3PG) to 2-phosphoglycerate (2PG); the results show that cell death occurred 
preferentially in lung cancer cells compared to normal cells. Additionally, the heterogeneous NPs 
comprising of KGF-ELP and PGM-ELP selectively enhanced killing in lung cells with high 
levels KGFR. Finally, the synthesis of a fusion proteins consisting of four PGM domains fused 
to ELP, (PGM)4-ELP, exhibits higher cytotoxic effect and efficiency when compared to the 
single PGM domain fusion, PGM-ELP.  
 Overall, we conclude that targeting overexpressed growth factor receptors to stimulate 
macropinocytosis can be a tremendously selective therapy for the treatment of lung cancer. This 
can result in attenuating side effects and improvement of the patient’s prognosis. 
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CHAPTER 1: INTRODUCTION 
 
1.1 The Lungs 
 The lungs are a pair of spongy organs located in the thoracic cavity where they are 
protected by the rib cage. They are divided into lobes. The right lung consists of three lobes: 
superior, middle and inferior. The superior and middle lobes are separated by a gap called the 
horizontal fissure; the oblique fissure separates the middle and inferior lobes. The left lung is 
smaller and comprised of only two lobes, superior and inferior, separated by an oblique fissure, 
Figure 1.1. 
 The main function of the lungs is the oxygenation of blood and removal of carbon 
dioxide (CO2). To achieve this gas exchange air travels deep into the lungs through structures 
named air passages. First, air is inhaled through the nose or mouth, and then it continues to the 
trachea, which splits into two branches, the bronchi. The air continues its path into smaller 
branches of the bronchi called bronchioles, which end in air sacs called alveoli. The alveolus is 
the site where gas exchange actually occurs. Capillaries cover the alveoli and bring blood that 
has been depleted of oxygen (O2) and is rich is CO2 in contact with the alveoli which have high 
concentration of O2 and low concentration of CO2. Because of the different in concentration, O2 
diffuses into the blood stream while CO2 travels into the alveoli, Figure 1.2.  
 The oxygenation of blood is a very critical process; O2 in the blood is delivered to all 
different tissues in the body, cells in these tissues use it to produce energy in the form of ATP. 
Life could not be sustained without O2. Just as important is the removal of CO2. This gas is a 
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byproduct of respiration and its accumulation in the body can cause the blood to become acidic 
Increase in the acidity of the blood can damage the function of vital organs such as the brain.  
1.2 Lung Cancer 
 Lung cancer is the abnormal, uncontrolled growth of cells in the lungs, usually 
originating from the epithelial cells in the air passages. This uncontrolled growth can result in the 
formation of a mass of cells called a lung tumor. Tumors may remain at the site where they 
originated in which case they are considered to be benign; contrastingly, tumors may also spread 
to other parts of the body in which case they are identified as malignant. The spreading of cancer 
cells over the body is termed metastasis and makes the treatment of any cancer very challenging.  
 The American Cancer Society recognizes three main types of lung cancers: Non-Small 
Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Lung Carcinoid Tumors. The 
frequency of each of these types of lung cancer varies considerably with NSCLC being the most 
common with 85% prevalence, while SCLC and Lung Carcinoid Tumors only represent 15% and 
5%, respectively [1]. Lung cancer is associated with factors that include smoking, exposure to 
second hand smoking, exposure to chemicals such asbestos, and even air pollution [2].  
 There are more than one hundred types of cancer; among which, lung cancer is the 
leading cause of death in the United States [3]. The American Cancer Society estimated 221,200 
new cases and 158,040 deaths due to lung cancer in the year 2015. Lung cancer is responsible for 
28% of cancer related deaths in the United States; this is more than the mortality rate of the next 
four most common cancer types (colon, breast, prostate, pancreas) combined [4], Figure 1.3. In 
addition, the 5-year observed survival rate is low; it varies from 49% to 1%. The variation 
depends on the stage at which the cancer was detected. 
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1.3 Stages of NSCLC 
 As discussed above, lung cancer is the uncontrolled growth of cells in the lungs. 
Continued growth can result in the invasion of nearby tissues and organs. Furthermore, cancer 
can expand to distant organs and tissues through the lymphatic system or the blood stream. The 
characterization of this progression in size and spreading is called staging. Staging is important 
because it allows the identification of proper treatment as well as the prognosis of the patient. 
Staging can also determine if a patient is suitable to be part of a clinical trial. The following 
stages are used for NSCLC: occult stage, stage 0, stage I (A and B), stage II (A and B), stage III 
(A and B), and stage IV [5]. 
 Briefly, the occult stage is the earliest stage at which NSCLC can be detected. In this 
stage, cancer has not metastasized but remains in situ. Cancer cells can be found in the sputum. 
In stage 0, abnormal cells can be found in the lining of the lungs. These cells are localized; 
therefore, this stage is also called carcinoma in situ. In stage I, a tumor has formed. This stage is 
further subdivided depending on the size and invasion. In stage IA, the tumor is less than 3 cm 
while in stage IB the tumor is between 3 and 5 cm. and may have spread to the bronchus or may 
have invaded the inner membrane that covers the lung.[5]. Stage II is characterized by the 
spreading of the tumor to the lymph node located on the same side of the tumor. Furthermore, 
stage IIA is characterized by a size that is less than 5 cm while stage IIB size is between 5 and 7 
cm. In stage III, cancer can be of any size and spread to the lymph nodes of the same side of the 
tumor. In addition in stage IIIA, other structures may have also been invaded such as the chest 
wall, diaphragm, and the membrane around the heart. Similarly, in stage IIIB, cancer is present 
in the lymph nodes and can be of any size. In addition to the structures that are invaded during 
stage IIIA, in this stage the cancer may have also spread to the esophagus, the trachea, and the 
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heart. In stage IV, cancer may have all the characteristics of the previous stages; in addition, 
tumors will be present in both lungs. Moreover, the cancer has spread to various organs such as 
the brain and the liver. 
1.4 Common Lung Cancer Treatments for NSCLC 
 The treatment of choice for lung cancer as well as any other cancer depends on several 
aspects: stage of cancer, patient’s health, side effects, and presence of other lung complications 
such as bronchitis. The most common options for the treatment of lung cancer include surgery, 
radiation therapy, chemotherapy, targeted therapy or a combination of the aforementioned. 
1.4.1 Surgery 
 Lung surgery is very complex and is mainly limited to the removal of tumors that have 
not metastasized. In addition, the patient’s health and lung functionality need to be addressed 
before surgery can be conducted; therefore, surgery is not always an option. However, surgery 
remains the best alternative to cure NSCLC. Studies have shown that surgery complemented 
with chemotherapy and/or radiation therapy has further improved the outcome in early stages of 
NSCLC [6]. Furthermore, after the removal of a lung mass by surgery, there is a 1% to 2% risk  
of recurrence [7]. The types of lung surgery for the removal of a lung tumor include 
segmentectomy, lobectomy, and pneumonectomy; the choice depends on whether part of a lobe, 
a lobe or the entire lung needs removal, respectively. 
1.4.2 Radiation Therapy  
 This type of therapy involves the use of ionizing radiation such as x-rays or gamma rays. 
Radiotherapy can be used as a primary treatment or an adjuvant treatment. The main goal 
radiation therapy is to shrink tumors and/or kill cancer cells. Similar to surgery, the use of 
radiation therapy is limited to localized tumors. In addition, there are limits to the amount of 
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radiation lungs and other organs can be exposed to without causing irreversible damage. This 
therapy however offers an alternative for stage I NSCLC patients for whom surgery is not an 
option. Studies have suggested that this type of therapy may have cure rates equivalent to surgery 
in stage I patients [8]. 
1.4.3 Chemotherapy  
 Chemotherapy consists of the use of anti-cancer drugs; the function of these drugs is 
mainly targeting fast dividing cells. Contrary to surgery and radiation therapy that are commonly 
used when the cancer is localized, chemotherapy can act throughout the body, which allows for 
the treatment of cancer that has already metastasized. However, this inherent characteristic of 
chemotherapeutic drugs can also affect non-cancerous cells that divide quickly such as red blood 
cells and epithelial cells lining the intestines. Therefore, even though chemotherapy is commonly 
used to treat lung cancer, it involves the indiscriminate killing of normal, healthy cells resulting 
in side effects. Furthermore, the development of resistance to chemotherapeutics often occurs, 
making this therapy, in many cases, ineffective over a period of time. Several chemotherapeutic 
drugs have been developed, they include DNA damaging drugs such as cisplatin or doxorubicin, 
and mitotic inhibitors such as paclitaxel [9]. However, due to significant side effects such as 
nephrotoxicity that may result from its nonspecific systemic organ distribution and inadequate 
intratumor concentrations, researchers are developing therapeutic agents that selectively affect 
tumor cells, targeted therapy. 
1.4.4 Targeted Therapy 
 The goal of targeted therapy is to minimize side effects associated with the unselective 
killing of cells due to chemotherapeutics. Targeted therapy exploits differences between normal 
and cancerous cells. One of the most popular targets for lung cancer is the epidermal growth 
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factor receptor (EGFR) that is overexpressed in 50 % to 90 % of lung cancers [10, 11]. 
Consequently, monoclonal antibodies against the EGFR (cetuximab) and tyrosine kinase 
inhibitors (TKI) that inhibit the tyrosine kinase activity of EGFR (erlotinib or gefitinib) have 
been developed and have shown mixed results in the treatment of lung cancer in several clinical 
trials [9]. Although, TKIs show good response rates in lung cancer patients, acquired resistance 
to TKI treatment always develops after a median of 10 months from the initiation of treatment 
[12]. This acquired resistance can be attributed to several factors such as secondary mutation of 
the EGFR gene, amplification of the MET gene or overexpression of HGF [12]. The issue of 
acquired resistance is present not only in TKI treatment but in all other chemotherapy treatments 
as well, since tumor cells bypass the pathways that these drugs target; rendering the drugs 
ineffective. Therefore, patient prognosis still remains poor with 5-year survival rate of less than 
5% and a median survival of approximately 1 year. 
1.5 Novel Strategy for Targeting NSCLC Cells 
 Current targeted therapies aim at blocking growth factor receptors to prevent cells from 
proliferating and growing. The problem faced by this strategy is that cancer cells are highly 
mutagenic and a minimal change in the target renders the therapy ineffective. In this thesis, we 
look into a novel strategy that takes advantage of overexpressed growth factor receptor and use 
them to selectively enhance the endocytotic mechanism of macropinocytosis (chapter 3). This 
stimulation occurs through the activation of the keratinocyte growth factor receptor (KGFR), 
which has been reported to be overexpressed in lung cancer [13, 14]. Furthermore, this activation 
is used to deliver a mitochondriotoxic peptide (Chapter 3) or a glycolytic inhibiting peptide 
(Chapter 4) to KGFR overexpressing cells.  
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1.6 Summary 
 Lung cancer is the leading cause of death among all the different cancer types, being non-
small cell lung cancer (NSCLC) the most common with an 85% incidence. There are different 
options for the treatment of this type of cancer including surgery, radiotherapy, chemotherapy, 
targeted therapy, and a combination of the aforementioned. The treatment of choice depends on 
various aspects such as stage of the cancer and health of the patient. Although much progress has 
been achieved in the treatment of lung cancer, the 5-year survival rate remains as low as 5% with 
a median survival of approximately 1 year. Furthermore, the issue of acquired resistance and the 
recurrence of the cancer seem to be a common theme regardless of the treatment of choice. 
Altogether, there is a clear need for further research and development of novel therapies for the 
treatment of lung cancer. 
 
 
Figure 1.1 Anatomy of the lung and related structures [15]. 
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Figure 1.2 Gas exchange in the alveoli [16]. 
 
Figure 1.3 Mortality rates of different cancer types [1]. 
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CHAPTER 2: (KLAKLAK)2 -ELP CAUSES APOPTOSIS THROUGH 
MITOCHONDRIAL DEPOLARIZATION 
 
2.1 Note to Reader 
 Part of this chapter was published in Medical Oncology: R. Iglesias and P. Koria, 
"Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer," Med 
Oncol, vol. 32, p. 259, Dec 2015. Permission is included in Appendix B. 
2.2 Introduction 
 KLAKLAKKLAKLAK, (KLAKLAK)2, is a peptide that disrupts the outer mitochondrial 
membrane once uptaken by cells. However, cells are impermeable to it; therefore, its cytotoxic 
effect in mammalian cells is hindered. In this chapter we show that the fusion comprising of 
(KLAKLAK)2 and elastin like polypeptide (ELP), (KLAKLAK)2-ELP, is internalized by cells. 
Surprisingly, the functionalization of the fusion was not required as others have suggested. 
Furthermore, the fusion retains the self-assemble property of ELPs and the bioactivity of 
(KLAKLAK)2; therefore, the fusion causes mitochondrial depolarization. We also show that the 
ELP domain of the fusion interacts with heparan sulfate proteoglycan (HSPG) on the cell 
surface. Moreover, we establish that (KLAKLAK)2-ELP is internalized by the transient, 
endocytotic mechanism of macropinocytosis.  
2.3 Elastin Like Polypeptide (ELP) 
 Elastin like peptides (ELPs) are biodegradable, non-immunogenic protein-based 
polymers composed of tandemly repeated blocks of (Val-Pro-Gly-X-Gly)N where X can be any 
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residue but Pro [1-3]. This sequence motif is derived from the hydrophobic domain of 
tropoelastin, a soluble precursor form of elastin. An interesting property of ELPs is their ability 
to undergo a phase transition at physiological temperatures [4, 5]. When the temperature is below 
their inverse transition temperature, also known as the lower critical solution temperature 
(LCST), they assume a random coil structure and are soluble in aqueous solution. However, at 
temperatures higher than the LCST, ELPs undergo an entropy driven self-assembly rendering 
them insoluble. This property enables recombinant ELPs to be expressed in bacteria and rapidly 
purified to high homogeneity using inverse temperature cycling (ITC) [2, 6]. Since ELPs are 
genetically encodable, biologically active peptides or proteins can be genetically fused to ELPs. 
These fusions can be expressed and readily purified since they maintain the phase transitioning 
property of the fused ELP domain. Moreover, owing to the transition property of ELPs, the 
chimeric fusion proteins can self-assemble into nanoparticles [7, 8]. Finally, the biological 
activity of the fused moiety in the chimeric fusion is retained [9, 10].  
2.4 Mitochondriotoxic Peptide (KLAKLAK)2 
 (KLAKLAK)2, is a synthetic 14-amino acid peptide whose structure was designed to 
mimic natural occurring antimicrobial peptides [11]. These peptides are usually characterized by 
their positive charge as well as their alpha helix structure [12]. Their selective antimicrobial 
action is attributed to the difference in overall membrane charge between bacterial and 
mammalian cells; bacterial membranes have an overall negative charge while mammalian cells 
are neutral. This translates to the higher transmembrane potential observed in bacterial cells. This 
same high transmembrane potential is also noted in the mitochondria, an organelle the main 
function of which is the production of energy through the electron transport chain (ETC). The 
ETC consist of a series of molecules whose main function is the creation of a proton gradient 
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which drives the production of ATP. Among those molecules that are part of the ETC is 
Cytochrome c (cyt c). Cyt c is a small molecule that when released to the cytoplasm causes cell 
death, apoptosis. 
 (KLAKLAK)2 is an amphipathic molecule that has a high positive charge, it has been 
shown to interact with the mitochondria causing swelling and mitochondrial depolarization [13]. 
Its mode of action is speculated to be through the creation of pores on the outer mitochondrial 
membrane that disrupts the proton gradient resulting in swelling and eventual release of cyt c 
[14, 15]. For (KLAKLAK)2 to be effective, it must be internalized; however, mammalian cells 
are impermeable to (KLAKLAK)2. Previous works have demonstrated that when (KLAKLAK)2 
is part of a nanostructure, cells become more permeable to it [16, 17]. Therefore, we reasoned 
that creating the fusion (KLAKLAK)2-ELP would result in its internalization by taking 
advantage of the ELP phase transition characteristic above its T t.  
2.5 Fusion (KLAKLAK)2-ELP 
2.5.1 Materials and Methods 
2.5.1.1 Materials 
 Fetal bovine serum (FBS) and Dulbecco modified Eagle Medium (DMEM) were 
purchased from Life Technologies. The restriction enzymes and other enzymes used for cloning 
were purchased from New England Biolabs (Ipswich, MA). Dr. Haura from Moffit Cancer 
Center kindly donated A549 and HCC827 cells. The apoptotic peptide gene and ELP gene were 
purchased from GenScript (Piscataway, NJ). The miniprep and gel extraction kits were 
purchased from QIAGEN.  
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2.5.1.2 Synthesis of (KLAKLAK)2-ELP 
 The PUC57 plasmids containing the genes (VPGVG)5 , (VPGVG)2VPGCG(VPGVG)2  
and (KLAKLAK)2  were purchased from Genscript (Piscataway, NJ). The V40C2 encoding gene 
was made using the recursive direction ligation method as described previously [18]. The 
(KLAKLAK)2 gene was excised using PflMI and Bgll enzymes. These genes were then run on a 
0.08% agarose gel and extracted using a QIAquick Gel Extraction Kit. PflMI linearized the 
pUC19 vector containing the ELP sequence and the excised (KLAKLAK)2 gene was cloned in 
frame with the ELP gene.  This resulted in the pUC19 vector containing the (KLAKLAK)2-ELP 
fusion protein gene flanked by pfIMI and BgII sites. The sequences encoding for the fusion 
proteins were then removed from the pUC19 vector using pflMI and BgII enzymes and 
recovered by gel extraction as explained above. After extraction, these genes were cloned in a 
modified pET25b+ expression vector through SfiI site. This vector was modified to incorporate 
an SfiI cloning site for the cloning of the fusion protein. 
The pET25b+ vector containing the fusion protein gene was transformed into BLRD 
competent cells through heat shock at 42oC. A starting culture of 50 ml was inoculated overnight 
and added to a 1 L culture the next day. The 1 L culture was then grown overnight and 
subsequently purified by inverse transition cycling as described previously [19]. Figure 2.1 
shows a representation of the genes for (KLAKLAK)2 and ELP and the production of the fusion 
(KLAKLAK)2-ELP. Also, the illustration of the thermoresponsive property of the synthesized 
fusion above and below its Tt  is represented. 
2.5.1.3 Cell Culture  
 Cells were cultured in a humidified incubator at 370C and 5% CO2.  Cells were seeded on 
24 or 48-well plates until they were approximately 70% confluent. A549 and HCC827 (human 
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lung carcinoma) were grown in DMEM supplemented with 10% FBS and 1% AA (Complete 
Medium).  
2.5.1.4 Dynamic Light Scattering of (KLAKLAK)2-ELP 
 Lyophilized (KLAKLAK)2-ELP was resuspended in PBS to a final concentration of 50 
μM. The solution was filter using a 220 μm filter and transfer to a cuvette. The analysis was 
performed using Zetasizer Nano S at different temperatures (20oC and 37 oC). 
2.5.1.5 Transmission Electron Microscopy of (KLAKLAK)2-ELP 
 Lyophilized (KLAKLAK)2-ELP was diluted in PBS to a final concentration of 50 μM. 
Enough solution was added to a carbon-coated grid to cover its surface. The grid was placed on 
an incubator at 37 oC for the (KLAKLAK)2-ELP to form nanoparticles. Once adsorbed on the 
grid, the particles were stained with uranyl formate staining solution and analyzed at Electron 
Microscopy Core Lab in the Interdisciplinary Science Building at the University of South 
Florida. 
2.5.1.6 Mitochondrial Swelling 
 Cells (HCC827) were treated for 24 Hrs. with 50 μM of (KLAKLAK)2-ELP. After the 
treatment, cells were fixed with 2.5% glutaraldehyde in 100 mM phosphate buffer at pH 7. 
Following fixation, standard embedding protocol for resin section was followed. TEM imaging 
was performed at Electron Microscopy Core Lab in the Interdisciplinary Science Building at the 
University of South Florida. 
2.5.1.7 Mitochondrial Depolarization Assay 
 Cells (10,000/well) were seeded on 48-well plates using fresh complete media. After 24 
hours, cells were treated with the indicated treatment of (KLAKLAK)2-ELP or (KLAKLAK)2 
peptide. A JC-1 assay kit (Life Technologies cat # M34152) was used for mitochondrial 
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depolarization analysis. After treatment, media was removed and cells were washed with ice-
cold PBS. JC-1 was added to fresh media to a final concentration of 2uM and this was added to 
the cells for 1 hour after which media was removed and cells were washed with ice-cold PBS 
before fluorescent pictures were taken (10X magnification) using EVOS fluorescence 
microscope (Life technologies). For the positive control sample, Carbonylcyanide m- 
chlorophenylhydrazone (CCCP) to a final concentration of 50 uM was added simultaneously 
with JC-1.  
 Mitochondrial depolarization analysis was also performed using flow cytometry. Cells 
(50,000/well) were seeded on 24 well plates and let grow to about 70% confluency; after which, 
they received no treatment, CCCP treatment or (KLAKLAK)2-ELP treatment.; one sample 
(assay control) was used for gating purposes. The CCCP treatment was added 30 minutes before 
analysis. After (KLAKLAK)2-ELP treatment for 24 hours, cells were washed with PBS and 
trypsinized (0.25 % trypsin). Trypsin was removed by centrifugation (800 rpm) and cells were 
resuspended in 300 μl of PBS. To exclude non-viable cells, 4',6-diamidino-2-phenylindole 
(DAPI) was added to the samples before analysis. Cells were analyzed using flow cytometry and 
the intensity in the red (PI) and green (FITC) channels were reported. 
2.5.1.8 Labeling of the Fusion Proteins 
 The cysteines present in the ELP sequence were labeled using maleimide chemistry for 
the particle internalization experiments. Fluorescein-5-maleimide (AnaSpec Inc cat # 81405) was 
mixed with the fusion proteins. The mixture was placed on an orbital shaker and incubated at 
room temperature for 2 hours. Unconjugated fluorescein was removed by a series of hot and cold 
cycles on a bench top centrifuge ran at a speed of 20000g for 10 minutes each time. The 
supernatant was discarded after the hot spin and an equal amount of cold sterile PBS was added. 
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This mixture was spun at 4 0C and the supernatant was collected while the pellet was discarded. 
This formed one complete cycle of inverse temperature cycling. To get rid of all the 
unconjugated fluorescein, at least 5 cycles were performed.  
2.5.1.9 Fusion Protein Internalization Assay 
 Cells (50,000/well) were seeded in 24-well plates and cultured as described above. They 
were let grow until they were about 70% confluent and were treated with the indicated 
treatments. For analysis, cells were washed twice with ice-cold PBS and were trypsinized using 
0.25% trypsin (100 μl). Cells were pelleted and re-suspended in 300 μl of PBS containing 50 
-diamidino-2-
phenylindole (DAPI) to allow exclusion of nonviable cells. The cells were analyzed using flow 
cytometry and either the percent of fluorescent cells or the average intensity was quantified and 
reported.  
 Some wells were pre-treated for 30 minutes with either inhibitors of macropinocytosis 
(amiloride and wortmannin) or receptor-mediated endocytosis (chlorpromazine). After the pre-
treatment, cells were treated with the indicated labeled fusion proteins and internalization was 
measured by flow cytometry as described above. The inhibitor concentrations were used as 
described previously [20]
heparan sulfate proteoglycans (HSPG) or the elastin receptor, cells were pre-treated with either 
20mIU/ml) or lactose (5 mM).  
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2.5.1.10 Live/Dead Assay 
 Cells were seeded and treated with the indicated treatments for 3 days. After their 
respective treatments, ethidium homodimer-1 (Life Technologies cat # E1169) was added to 
each well to a final concentration of 4uM. Cells were then incubated for 1 hour at 37oC. After the 
incubation time, cells were washed twice with PBS to remove floating cells. NucBlue (Life 
Technologies R37605) was then added for 20 minutes to stain nuclei, followed by two washes 
with PBS. Eight random pictures were taken per well using the EVOS fluorescence microscope 
(10X magnification). Pictures were taken in different channels (blue, green, red) and overlay. 
Live/dead cell discrimination was performed using image J.  A macro was created using the 
functions split channel, threshold, and cell counter to count the total number of live cells (blue) 
in each picture. Dead cells that were not removed after the washes were stained red or magenta 
(blue and red); adjusting the threshold for the picture being analyzed easily isolated these cells. 
Therefore, the final count of cells per picture only included live cells.  
2.5.1.11 Statistical Analysis 
 For statistical significance, the p value was calculated using ANOVA single factor.  P 
values < 0.05 were considered significant. The reported errors indicate the ±SEM. 
2.5.2 Results 
2.5.2.1 (KLAKLAK)2-ELP Preserves the Phase Transition Property of ELPs 
 ELPs are genetically encodable; therefore, they are relatively easy to functionalize using 
simple recombinant DNA technology techniques. In addition, ELPs’ phase transition property 
makes them very appealing for the synthesis of nanoparticles that are thermoresponsive and 
allow for improve concentration of treatment to a site that has been exposed to a temperature that 
is equal to or higher than the ELP Tt [10, 21, 22] Many studies have shown that ELPs greatly 
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preserve this phase transition property when fused to other domains [23, 24]. Based on these 
studies, we tested if our fusion (KLAKLAK)2-ELP preserve the self-assemble property of ELPs. 
Our results clearly showed that (KLAKLAK)2-ELP is in its soluble form at a temperature of 20 
oC while it aggregates to a size of about 350 nm at a temperature of 37 oC (Figure 2.2). Since 
these experiments were carried out as a cycle, with one cycle consisting of increasing and 
decreasing the temperature from 20 oC to 37 oC and back, we concluded that the ELP self-
assemble property was retained. TEM further confirmed the size of the (KLAKLAK)2-ELP 
aggregate to be about 350 nm (Fig 2.3).  
2.5.2.2 (KLAKLAK)2-ELP Causes Mitochondrial Swelling 
 Previous work has shown that (KLAKLAK)2 causes mitochondrial swelling through the 
disruption of the outer mitochondrial membrane [13]. We wanted to confirm that our fusion 
(KLAKLAK)2-ELP had the same toxic effect in cells. TEM analysis of our samples clearly 
indicated a difference between the mitochondria of the control compare the mitochondria of the 
(KLAKLAK)2-ELP treated sample (Figures 2.4 and 2.5). Therefore, we concluded that the mode 
of action of our fusion is similar to the (KLAKLAK)2 peptide. 
2.5.2.3 (KLAKLAK)2 Fused to ELPs Induces Cell Death Via Mitochondrial Depolarization 
 Previous studies have shown that (KLAKLAK)2 has low mammalian cell toxicity but can 
induce mitochondrial depolarization and subsequent apoptosis when fused to a homing domain 
[11, 13]. Furthermore, others have demonstrated that when (KLAKLAK)2 is part of a 
nanostructure that is functionalized with a cell penetrating peptide (CPP), it is internalized and 
causes cell death [16, 17].  Based on these findings, we fused (KLAKLAK)2 to elastin like 
peptides (ELP), (KLAKLAK)2-ELP, making it possible to form nanostructures as mentioned 
above. Surprisingly, after a 48-hour treatment, (KLAKLAK)2-ELP caused 30%, 85%, and 93% 
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of cell death at 20μM, 50μM and 100μM, respectively, without the need of a functionalizing 
domain. Moreover, the same treatment with the (KLAKLAK)2 peptide did not affect cell 
viability (Figure 2.6). To further test if cell death occurred due to mitochondrial depolarization as 
previously reported, we performed a JC-1 assay that distinguishes between healthy and 
depolarized mitochondria. This assay stains healthy mitochondria in red and depolarized 
mitochondria in green. After a 24 Hr. treatment with the (KLAKLAK)2-ELP fusion, cells 
displayed the presence of depolarized mitochondria, (Figures 2.7 and 2.8). Combined, these 
results suggest that the (KLAKLAK)2-ELP nanostructure caused cell death through 
mitochondrial depolarization even in the absence of a functionalized domain.  
2.5.2.4 Internalization of (KLAKLAK)2-ELP is Assisted by HSPG on the Cell Surface 
 Since the lack of a functionalizing domain in (KLAKLAK)2-ELP still resulted in cell 
death, we reasoned that ELPs might be involved in the uptake of (KLAKLAK)2-ELP.  Previous 
works have found that ELPs interact with the elastin receptor [25]. Furthermore, tropoelastin 
from which ELPs are derived interacts with HSPG on the cell surface [26]. Thus, we 
hypothesized that the internalization of (KLAKLAK)2-ELP could also be mediated by the 
interaction between the ELP portion of the fusion and one of these aforementioned molecules. 
To test this hypothesis, we carried out experiments in the presence of molecules that block the 
elastin receptor (lactose), cleave HSPG (heparinase III) or serve as a HSPG antagonist (surfen)  
[27]. First, cells were pretreated with lactose that binds to the elastin receptor preventing other 
molecules from binding to it. The presence of lactose did not affect the internalization of 
(KLAKLAK)2-ELP (Figure 2.9) suggesting that the elastin receptor is not involved in the 
internalization. Second, we pretreated the cells with heparinase III that cleaves HSPG from the 
cell surface. Our results showed a 70% decrease in (KLAKLAK)2-ELP internalization when 
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compared to control (Figure 2.9). Finally, to further confirm that HSPG was involved in 
(KLAKLAK)2-ELP internalization, cells were pretreated with surfen, which is a small molecule 
antagonist to HSPG [27]. The result showed that about 90% of (KLAKLAK)2-ELP 
internalization was blocked (Figure 2.9). Thus, these results clearly indicate that the 
internalization of (KLAKLAK)2-ELP depends on its interaction with HSPG. 
2.5.2.5 (KLAKLAK)2-ELP is Internalized by Macropinocytosis 
 To gain insight into the mechanism of uptake of (KLAKLAK)2-ELP aggregates, we used 
known blockers for two major endocytotic pathways. Chlorpromazine was used to block clathrin 
mediated endocytosis, amiloride and wortmannin to block macropinocytosis. Internalization 
experiments were carried out in the presence of each of these blockers using concentrations 
previously determined [20]. The results showed that (KLAKLAK)2-ELP uptake was not affected 
by chlorpromazine; however, amiloride and wortmannin decreased (KLAKLAK)2-ELP 
internalization by 70% and 75% , respectively (Figure 2.10). Altogether, these results indicate 
that macropinocytosis is the major mechanism involved in (KLAKLAK)2-ELP internalization.  
2.6 Discussion and Summary 
 The mitochondriotoxic peptide (KLAKLAK)2 is well known to disrupt the outer 
mitochondrial membrane causing swelling and mitochondrial depolarization; this translates to 
cell death. However, as demonstrated by others and us, cells are impermeable to (KLAKLAK)2; 
therefore, it has not cytotoxic effect unless it is uptaken by cells. Other groups have reported 
various strategies to improve (KLAKLAK)2 internalization by cells such as fusing it to cell 
penetrating peptides (CPP). Also, previous work suggested that (KLAKLAK)2 internalization 
can be improved by making it part of a nanoparticle in addition to functionalizing it with a CPP. 
Based on the latter, we synthesized (KLAKLAK)2-ELP, the ELP portion of the fusion provides 
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the nanoparticle backbone when expose to a temperature higher than its Tt.. Interestingly, we 
found that functionalization of the (KLAKLAK)2 was not needed to improve its uptake, but the 
nanoparticle formation was enough for its internalization and subsequent cell death. 
Furthermore, we show that (KLAKLAK)2-ELP causes mitochondrial swelling and 
depolarization; this is consistent with previously reported data. Therefore, our results clearly 
indicate that the cytotoxic mechanism of (KLAKLAK)2-ELP follows that of (KLAKLAK)2 
peptide. 
 We found that the predominant mechanism of uptake of (KLAKLAK)2-ELP 
nanoparticles by cells was macropinocytosis. Tumor cells exhibit higher levels of 
macropinocytosis than the normally quiescent non-cancerous cells [28, 29]. Thus, 
macropinocytosis on its own may provide certain level of selectivity towards killing of cancer 
cells. Indeed, it was observed that (KLAKLAK)2 nanoparticles demonstrated certain level of 
killing selectivity towards cancer cells [17]. Though, the mechanism of internalization was not 
reported in that study it is plausible that those nanoparticles were also being internalized by 
macropinocytosis thereby explaining the selectivity. 
 We also show that the internalization of ELP nanoparticles was dependent on their 
interaction with cell surface heparan sulfate proteoglycans (HSPG). This is in agreement with 
previous studies that have reported that tropoelastin from which ELPs are derived interacts with 
cell surface HSPG [26, 30]. The interaction of ELPs with HSPG may ensure proximity of the 
NPs to the cell surface where they will be uptaken by macropinocytosis. Interestingly, previous 
work has reported the importance of phase transition for the internalization of ELP based 
molecules [31].  Our data may explain this observation because during phase transition ELPs 
form β-strand structure, which has been reported as a common secondary structure for variety of 
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proteins that interact with cell membrane bound HSPG [32]. Thus, the phase transition allows 
ELPs to interact with HSPG facilitating its internalization. 
 In summary, we found that the fusion (KLAKLAK)2-ELP is mitochondriotoxic without 
the need to be functionalized; the nanoparticle conformation provided by the ELP backbone was 
enough to cause the internalization and cytotoxicity of the fusion. Furthermore, cell death occurs 
via mitochondrial depolarization and swelling. We found that the mechanism of internalization 
of (KLAKLAK)2-ELP is macropinocytosis; we believe the interaction between the ELP domain 
of the fusion and heparan sulfate on the cell membrane allows for the proximity required for 
macropinocytosis to act on the (KLAKLAK)2-ELP nanoparticles 
Table 2.1 (KLAKLAK)2 and ELP amino acid sequences. 
(KLAKLAK)2  KLAKLAKKLAKLAK 
ELP V40C2 
V VPGVG 
C (VPGVG)2-VPGCG-(VPGVG)2 
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Figure 2.1 Representation of (KLAKLAK)2-ELP synthesis and its thermoresponsive property. 
Top, representation of (KLAKLAK)2 gene, the ELP, and their translation to the fusion 
(KLAKLAK)2-ELP. Bottom, illustration of the phase transition property of the fusion above and 
below its transition temperature (Tt). The fusion is soluble below its Tt and aggregates above its 
Tt. 
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Figure 2.2 Characterization of (KLAKLAK)2-ELP by dynamic light scattering. (KLAKLAK)2-
ELP retains the self-assemble property of ELPs. Lyophilized (KLAKLAK)2-ELP resuspended in 
PBS to a final concentration of 50 μM was analyzed by DLS at 20 oC and 37 oC.. The graph 
shows clearly two peaks at about 5 nm and 350 nm representing the (KLAKLAK)2-ELP as 
unimers and as aggregates, respectively. 
 26 
 
Figure 2.3 TEM of (KLAKLAK)2-ELP. This fusion protein aggregates to a size of about 360 nm 
as confirmed by TEM. (KLAKLAK)2-ELP was adsorbed on a carbon-coated grid, incubated at 
37 oC and stained with uranyl formate. Bar = 200 nm. 
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Figure 2.4 TEM of normal mitochondria. HCC827 were imaged by TEM. Red arrows show the location of the mitochondria. 
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Figure 2.5 TEM of mitochondrial swelling. HCC27 cells were treated with 50 μM of (KLAKLAK)2-ELP for 24 Hrs. Cells were then 
imaged by TEM. Red arrows indicate the location of the elongated mitochondria.  
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Figure 2.6 Cytotoxic effect of (KLAKLAK)2-ELP and (KLAKLAK)2 peptide. (KLAKLAK)2-
ELP induces cell death at high concentrations while the (KLAKLAK)2 peptide does not. Lung 
adenocarcinoma cells, A549, were treated for 48 Hrs. with different concentrations of 
(KLAKLAK)2-ELP or (KLAKLAK)2 peptide. The percent of live cells was calculated using a 
live/dead assay; pictures were then taken using a fluorescent microscope and the counting was 
done using image J. All the treatments were normalized to the control (no treatment). 
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Figure 2.7 Mitochondrial depolarization analysis by flow cytometry. A549 cells were treated for 
24 Hr. with 10μM of (KLAKLAK)2-ELP or 30 min. with a known mitochondrial depolarizer, 
CCCP. A JC-1 assay, which distinguishes between healthy and depolarized mitochondria, was 
then performed. Analysis was carried out by flow cytometry. The assay control is for gating 
purposes; the negative control consisted of untreated cells. The apoptotic label shows the area 
where cells with depolarized mitochondria are found while the non-apoptotic label shows the 
area where cells with healthy mitochondria are found. The results clearly show the 
mitochondriotoxic effect of (KLAKLAK)2-ELP. PI-A and FITC-A refer to red and green 
fluorescent channels, respectively. 
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Figure 2.8 Mitochondrial depolarization analysis by fluorescent microscopy. Cells were treated with either 10 μM of (KLAKLAK)2-
ELP or CCCP diluted to a final concentration of 50 μM. The control consisted of untreated cells. Mitochondria are stained red 
(healthy) or green (depolarized). The results clearly show that the fusion (KLAKLAK)2-ELP causes mitochondrial depolarization. Bar 
= 400μm. 
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Figure 2.9 (KLAKLAK)2-ELP internalization after blocking the elastin receptor complex and 
heparan sulfate proteoglycan. A549 cells were pretreated with lactose, Heparinase III, or surfen 
for 30 minutes, except for control. These cells were then treated with 10μM of labeled 
(KLAKLAK)2-ELP for 24 Hrs. The percent of cells uptaking the treatment was quantified by 
flow cytometry. To make sure that only internalized (KLAKLAK)2-ELP was quantified, trypan 
blue was added to the cell suspension before analysis to quench any labeled molecule bound to 
the cell surface. This experiment was repeated two times with triplicates. * indicates p < 0.05 
when compared to control. 
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Figure 2.10 (KLAKLAK)2-ELP internalization after blocking receptor mediated endocytosis and 
macropinocytosis. A549 cells were pretreated with chlorpromazine (receptor-mediated 
endocytosis blocker), wortmannin or amiloride (macropinocytosis blockers) for 1 Hr. The cells 
were then treated with 10μM of labeled (KLAKLAK)2-ELP for 24 Hrs. in the presence of the 
blockers before analysis by flow cytometry. Trypan blue was added to the cell suspension before 
analysis to prevent including particles that may be bound to the cell surface. This experiment was 
repeated two times with triplicates. * indicates p < 0.05 when compared to control.  Error bars 
represent ±SEM. 
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CHAPTER 3: KGF-ELP ENHANCES MACROPINOCYTOSIS IN KGFR 
OVEREXPRESSING CELLS 
 
3.1 Note to Reader 
 Part of this chapter was published in Medical Oncology: R. Iglesias and P. Koria, 
"Leveraging growth factor induced macropinocytosis for targeted treatment of lung cancer," Med 
Oncol, vol. 32, p. 259, Dec 2015. Permission is included in Appendix B 
3.2 Introduction 
 In this chapter we show that the fusion of the keratinocyte growth factor (KGF) and 
elastin like polypeptide (ELP), KGF-ELP, selectively enhances macropinocytosis in keratinocyte 
growth factor receptor (KGFR) overexpressing cells. Furthermore, we demonstrate that this 
selectivity can be further used to improve the internalization of the fusion (KLAKLAK)2-ELP 
discussed in the previous chapter. Finally, the heterogeneous nanoparticle comprising of KGF-
ELP and (KLAKLAK)2-ELP clearly improves the cytotoxic effect of (KLAKLAK)2-ELP in 
KGFR overexpressing lung cancer cells. 
3.3 Keratinocyte Growth Factor (KGF) 
 Growth factors are proteins whose functions include cell proliferation, migration, and 
differentiation [1]. The mode of action of these molecules is through their interaction with their 
receptor on the cell surface. Once this interaction occurs, intracellular signaling occurs that 
permits the cell to undergo several changes resulting in the functions mentioned above.  
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 Much emphasis has been placed on growth factor receptors as target for cancer 
treatment.[2-4] It is well known that a common characteristic of several cancer types is the 
overexpression of growth factor receptors such as the epidermal growth factor receptor (EGFR) 
[5, 6] and the keratinocyte growth factor receptor (KGFR) [7-9]. Therefore, one method used for 
targeted treatment has aimed at blocking the extracellular domain of these receptors using 
monoclonal antibodies (mAb); so that, the ligand/receptor interaction is loss and proliferation is 
halted [10]. However, mAb are highly specific and a minor change in their target makes them 
ineffective. Another way that has been used to target receptors is the use of small molecules that 
block the intracellular domain of the receptors so that signaling pathways are not activated when 
the ligand/receptor binding occurs [11]. However, the highly mutagenic nature of cancer cells 
can develop an alternative pathway rendering the treatment unproductive.  
 Others have looked at the interaction between growth factor and its receptors as an 
opportunity to selectively deliver cytotoxic cargo to cells overexpressing a receptor. For instance, 
once the ligand/receptor interaction occurs, the process of receptor mediated endocytosis (RME) 
initiates [12]. In addition, another internalization process that has been recently gaining more 
interest is macropinocytosis [13]. This transient process can also be activated or enhanced by 
growth factors and offers several advantages when compared to RME. For instance, 
macropinocytosis allows for the uptake of several molecules on the cell periphery while RME is 
limited to molecules that are in the areas where the interaction occurs. 
 One of the most common targets in lung cancer is the EGFR. The downside of targeting 
EGFR is that it is ubiquitously express; thus, it is likely that targeting this receptor results in 
unwanted systemic toxicity due to its stimulation in normal tissue. KGFR has been identified as 
another receptor that is overexpressed in lung cancer [8, 14]. The advantage of using this 
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receptor over EGFR is that KGFR is not expressed ubiquitously; therefore, systemic toxicity may 
be diminished. Based on this, we opted to target KGFR. However, due to the simplicity of the 
system we describe in this chapter, other growth factor receptors can easily be targeted such as 
HGF [15] and EGF [16]. 
3.4 Macropinocytosis 
 Endocytosis is a process through which cells internalize nutrients, hormones, proteins, 
and lipids that are required for diverse cell functions such as their proliferation, growth and 
health maintenance. The vesicles formed during endocytosis fuse with endosomes for cargo 
sorting and then either recycle back to the cell membrane and their contents expelled out from 
the cell or they can fuse with lysosomes for subsequent degradation of the cargo. Endocytosis 
can be subdivided into clathrin-dependent and clathrin-independent endocytosis depending on 
whether the protein clathrin coats or not the formed vesicles, (Figure 3.1). 
 Clathrin-dependent endocytosis is also known as receptor mediated endocytosis (RME). 
It is the most studied and understood endocytotic mechanism. One major characteristic RME is 
that it internalizes macromolecules selectively. In addition, this process requires the interaction 
between a ligand and its cell membrane receptor; these receptors are found on regions called 
clathrin-coated pits. Upon ligand-receptor interaction, closure of these pits result in the formation 
of vesicles that are coated with the protein clathrin making them leak-proof; therefore, the cargo 
does not diffuse into the cytoplasm. As mentioned above however, these vesicles will fuse with 
endosomes for sorting of their contents and eventual recycle or degradation by lysosomes.  
 Many studies have focus on the use of RME as a targeted delivery mechanism for drugs 
to treat cancer. However, due to innate characteristics of this mechanism,  it also provides many 
challenges for its use. Other works have reported endosomal entrapment of their drugs [17-19]. 
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This occurs because of the leak proof vesicles formed during RME do not permit the diffusion of 
the drugs into the cytoplasm, lowering or preventing the efficacy of the treatment due its low 
intracellular concentration. Another limitation is the size constraint when using RME. RME 
vesicles have a diameter of about 100 nm, which limits the amount of therapeutics that can be 
internalized. Furthermore, lysosomal degradation may also prevent the treatment from being 
successful.  
 Macropinocytosis is one of the clathrin-independent endocytotic mechanisms; it is an 
actin-driven process. Unlike receptor-mediated endocytosis however, this process does not rely 
directly on cargo/receptor interaction for its activation [20]. Therefore, macropinocytosis is a 
non-specific internalization mechanism. It is a transient process in most cells and it can be 
stimulated by the interaction between growth factors, such as the keratinocytes growth factor 
(KGF) and epidermal growth factor (EGF), and their receptors [16, 21, 22]. This interaction 
leads to an increase in actin polymerization that will result in cell membrane extensions called 
ruffles. Falling back of these ruffles on the plasma membrane results on the formation of vesicles 
called macropinosomes, which are characterized for being large, uncoated and leaky vesicles 
[23-25].  
 Many of the innate characteristics of macropinocytosis make it an interesting targeted 
mechanism to look into for targeted therapy. As mentioned above, macropinocytosis is non-
selective; therefore, it can indiscriminately internalize molecules that are bound to the cell 
membrane without the need for a specific cargo/receptor interaction. Consequently, the 
interaction between a growth factor and its receptor resulting in enhanced macropinocytosis can 
cause the uptake of multiple molecules bound on the cells surface [26]. In addition, the leaky 
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nature of macropinosomes allows for the diffusion of the uptaken molecules to the cytoplasm 
avoiding endosomal entrapment.  
 Having learned in the previous chapter that ELPs interact with heparan sulfate on the cell 
surface, it makes us reason that this interaction may assist in the internalization of ELP fusion 
molecules by allowing them to be bound to the cell surface for macropinocytosis to act on them. 
In addition, we reasoned that a growth factor fused to ELPs could result in enhancement of 
macropinocytosis. Therefore, this chapter deals with the use a heterogeneous nanoparticle 
consisting of (KLAKLAK)2-ELP and KGF-ELP, figure 3.5. This multifunctional nanoparticle 
allows for the selective enhancement of macropinocytosis in cells overexpressing the 
keratinocyte growth factor receptor (KGFR). At the same time, due to the ELP domain, many of 
these nanoparticles will be bound on the cell surface of the cell; therefore, many of them could 
be internalized. Once inside the cell, the (KLAKLAK)2-ELP fusion will cause cell death due to 
mitochondrial depolarization as described in the previous chapter.  
3.5 KGF-ELP Fusion Selectively Enhances Macropinocytosis 
3.5.1 Materials and Methods 
 Fetal bovine serum (FBS) and Dulbecco modified Eagle Medium (DMEM) were 
purchased from Life Technologies. The restriction enzymes and other enzymes used for cloning 
were purchased from New England Biolabs (Ipswich, MA). H292, A549, H1650, H23, and 
HCC827 cells were kindly donated by Dr. Haura from Moffit Cancer Center. CRCL2522, 
fibroblasts, were purchased from ATCC (Manassas, VA). Human Small Airway Epithelial Cells 
(SAEC) cells were kindly donated by Dr. Narasaiah Kolliputi from the Department of Internal 
Medicine at USF Health. Growth factors and apoptotic peptide genes were purchased from 
GenScript (Piscataway, NJ). The miniprep and gel extraction kits were purchased from 
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QIAGEN. The reagents for real-time polymerase chain reaction (RT-PCR) were purchased from 
Bio-Rad. 
3.5.1.1 Synthesis of KGF-ELP 
 The PUC57 plasmids containing the genes (VPGVG)5 , (VPGVG)2VPGCG(VPGVG)2 ,  
and KGF were purchased from Genscript (Piscataway, NJ). The V40C2 encoding gene was made 
using recursive direction ligation method as described previously [27]. The KGF gene was 
excised using PflMI and Bgll enzymes. This gene was then run on a 0.08% agarose gel and 
extracted using QIAquick Gel Extraction Kit. The restriction enzyme PflMI linearized the 
pUC19 vector containing the ELP sequence and the excised KGF gene was cloned in frame with 
the ELP gene.  This resulted in the pUC19 vector containing the KGF-ELP fusion protein gene 
flanked by pfIMI and BgII sites. The sequences encoding for the fusion protein was then 
removed from the pUC19 vector using pflMI and BgII enzymes and recovered by gel extraction 
as explained above. After extraction, this gene was cloned in a modified pET25b+ expression 
vector through SfiI site. This vector was modified to incorporate a SfiI cloning site for the 
cloning of the fusion protein. 
 The pET25b+ vector containing the fusion protein gene was transformed into BLRD 
competent cells through heat shock at 42oC. A starting culture of 50 ml was inoculated overnight 
and added to a 1 L culture the next day. The 1 L culture was then grown overnight and 
subsequently purified by inverse transition cycling as described previously [28]. Figure 3.2 
shows a representation of the genes for KGF and ELP and the production of the fusion KGF-
ELP. 
 
 
 44 
3.5.1.2 Cell Culture  
 Cells were cultured in a humidified incubator at 370C and 5% CO2.  Cells were seeded on 
24 or 48-well plates until they were approximately 70% confluent.  CRL-2522 (non-malignant 
human foreskin fibroblast), A549 (human lung carcinoma), H292 (human lung carcinoma), 
HCC827 (human lung adenocarcinoma), H23 (human lung adenocarcinoma), and H1650 (human 
lung adenocarcinoma) were grown in DMEM supplemented with 10% FBS and 1% AA 
(Complete Medium). SAEC were cultured in airway epithelial cell basal medium (PCS-300-030) 
supplemented with Small Airway Epithelial Cell Growth Kit (PCS-301-040).  
3.5.1.3 Internalization of KGF-ELP  
 Cells (HCC827) were treated for 24 Hrs. with 50 μM of KGF-ELP. After the treatment, 
cells were fixed with 2.5% glutaraldehyde in 100 mM phosphate buffer at pH 7. Following 
fixation, standard embedding protocol for resin section was followed. TEM imaging was 
performed at Electron Microscopy Core Lab in the Interdisciplinary Science Building at the 
University of South Florida. Figure 3.3 shows the internalized KGF-ELP. 
3.5.1.4 Labeling of the Fusion Proteins 
 The cysteines present in the ELP sequence were labeled using maleimide chemistry for 
the particle internalization experiments. Fluorescein-5-maleimide (AnaSpec Inc cat # 81405) was 
mixed with the fusion proteins. The mixture was placed on an orbital shaker and incubated at 
room temperature for 2 hours. Unconjugated fluorescein was removed by a series of hot and cold 
cycles on a bench top centrifuge ran at a speed of 20000g for 10 minutes each time. The 
supernatant was discarded after the hot spin and an equal amount of cold sterile PBS was added. 
This mixture was spun at 4 0C and the supernatant was collected while the pellet was discarded. 
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This formed one complete cycle of inverse temperature cycling. At least 5 cycles were 
performed to remove of all the unconjugated Fluorescein.  
3.5.1.5 Fusion Protein Internalization Assay 
 Cells (50,000/well) were seeded in 24-well plates and cultured as described above. They 
were let grow until they were about 70% confluent and were treated with the indicated 
treatments. For analysis, cells were washed twice with ice-cold PBS and were trypsinized using 
0.25% trypsin (100 μl). Cells were pelleted and re-suspended in 300 μl of PBS containing 50 
-diamidino-2-
phenylindole (DAPI) to allow exclusion of nonviable cells. The cells were analyzed using flow 
cytometry and either the percent of fluorescent cells or the average intensity was quantified and 
reported.  
3.5.1.6 Dextran Assay 
 Twenty-four hours after the indicated treatment, dextran tetramethylrhodamine (Life 
Technolo
cytometry analysis, cells were washed at least five times with ice-cold PBS. The steps described 
above for flow analysis were then followed; however, trypan blue was not added. 
3.5.1.7 Gene Expression Using RT-PCR 
 Cells (500,000/well) were seeded on 6-well plates and let grow to about 80% confluency. 
RNA was isolated using the SV Total RNA isolation System (Promega cat # Z3100). cDNA 
synthesis was done using iScript cDNA synthesis Kit from BIO-RAD (cat # 1708890) following 
manufacturer’s protocol. RT-PCR was performed using BIO-RAD C1000 Thermal Cycler. The 
following primers were used for the KGFR cDNA amplification: forward primer 
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CAATTATATAGGGCAGGCCAACCAG and reverse primer AAGAAGACCCCTATGCAGT-
AAATGG. 
3.5.1.8 Live/Dead Assay 
 Cells were seeded and treated with the indicated treatments for 3 days. After their 
respective treatments, ethidium homodimer-1 (Life Technologies cat # E1169) was added to 
each well to a final concentration of 4uM. Cells were then incubated for 1 hour at 37oC. After the 
incubation time, cells were washed twice with PBS to remove floating cells. NucBlue (Life 
Technologies R37605) was then added for 20 minutes to stain nuclei, followed by two washes 
with PBS. Eight random pictures were taken per well using the EVOS fluorescence microscope 
(10X magnification). Pictures were taken in different channels (blue, green, red) and overlay. 
Live/dead cell discrimination was performed using image J.  A macro was created using the 
functions split channel, threshold, and cell counter to count the total number of live cells (blue) 
in each picture. Dead cells that were not removed after the washes were stained red or magenta 
(blue and red); adjusting the threshold for the picture being analyzed easily isolated these cells. 
Therefore, the final count of cells per picture only included live cells.  
3.5.1.9 Statistical Analysis 
 For statistical significance, the p value was calculated using ANOVA single factor.  P 
values < 0.05 were considered significant. The reported errors indicate the ±SEM.  
3.5.2 Results 
3.5.2.1 KGF-ELP Enhances Internalization of (KLAKLAK)2-ELP in KGFR Over-
expressing Cells 
 Macropinocytosis is a non-specific internalization process that results from cell ruffling; 
furthermore, this process can be enhanced by growth factors [21]. Therefore, we reasoned that a 
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treatment that includes growth factors could selectively enhance macropinocytosis in growth 
factor receptor expressing cells. Earlier work has reported the overexpression of the keratinocyte 
growth factor receptor (KGFR) in lung cancer cells [8]. Consequently, we used RT-PCR to 
measure the expression of this receptor in several cell types including five lung cancer cell lines 
and two noncancerous cell lines (Figure 3.4). We selected A549 cells for subsequent experiments 
since they had the highest expression of this receptor. Our lab has previously synthesized the 
fusion comprising of KGF and ELP, KGF-ELP, this fusion is bioactive and self-assembles into 
nanostructures [28]. In order to test our hypothesis of selective enhancement of macropinocytosis 
we created heterogeneous particles comprising of KGF-ELP and (KLAKLAK)2-ELP (Figure 
3.5); the internalization analysis was carried out using flow cytometry. The results clearly show 
that the heterogeneous particles containing (KLAKLAK)2-ELP improved (KLAKLAK)2-ELP 
uptake by 21 folds compared to homogeneous particles consisting of (KLAKLAK)2-ELP only 
(Figure 3.6). Since adding KGF-ELP to the (KLAKLAK)2-ELP formulation results in an 
increased number of particles, we compared the uptake to homogeneous particles containing 
similar concentration of (KLAKLAK)2-ELP as well as heterogeneous particles comprising of 
non-functionalized ELP and (KLAKLAK)2-ELP (Figure 3.6). These data clearly suggest that 
inclusion of KGF-ELP in the NP formulation improved the uptake of (KLAKLAK)2-ELP in 
KGFR overexpressing cells. To further demonstrate the role of KGF-ELP in targeted 
internalization, we compared the (KLAKLAK)2-ELP uptake in fibroblasts, which do not express 
the KGFR. Indeed, the increase in (KLAKLAK)2-ELP uptake induced by the inclusion of KGF-
ELP was not observed in fibroblasts (Figure 3.7). 
 We further wanted to demonstrate the direct relation between KGF-ELP treatment and 
enhanced macropinocytosis. To accomplish this task, macropinosome formation was quantified 
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after a 24 Hr. treatment with 1μM, 10μM or 50μM of KGF-ELP on A549 cells. Fluorescent 
pictures were taken for visual representation (Figure 3.8). The results were quantified using flow 
cytometry. Our data clearly suggest a dose dependent effect on macropinosome formation in 
A549 cells (Figure 3.9).  To show that this effect is selective, fibroblasts were also treated with 
50μM of KGF-ELP as described above. The results showed no increase in macropinosome 
formation (Figure 3.10). Combined, the results clearly imply that KGF-ELP induces 
macropinocytosis selectively in KGFR expressing cells.  
3.5.2.2 KGF-ELP Improves the Cytotoxic Effect of (KLAKLAK)2-ELP in KGFR 
Overexpressing Cells 
 After showing that a formulation containing KGF-ELP improved the internalization of 
(KLAKLAK)2-ELP in KGFR overexpressing cells, we tested if this higher internalization would 
translate to targeted cytotoxicity. While there was no effect on fibroblasts, the combination 
treatment resulted in about 35 % cell death in cells that had very little KGFR expression (Figure 
3.11). Interestingly, the combination treatment resulted in nearly 50% to 70 % cell death in high 
KGFR expressing cell lines (Figure 3.11, A549, HCC827, and H1650). These data show that the 
combination treatment of KGF-ELP and (KLAKLAK)2-ELP resulted in significantly higher cell 
death in high KGFR expressing cell. 
3.6 Discussion and Summary 
 Targeted therapy is increasingly becoming popular for the treatment of lung cancer. 
Currently, growth factor receptor tyrosine kinase inhibitors that target highly expressed growth 
factor receptors in lung cancer are used for treatment [29]. Here, we describe an approach of 
targeting lung cancer cells by exploiting the malignant processes that are inherent to them. 
Specifically, we report the development of two chimeric fusion proteins namely (KLAKLAK)2-
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ELP and KGF-ELP that self-assemble into nanoparticles. In chapter 2 we showed that 
(KLAKLAK)2-ELP nanoparticles are internalized by cancer cells resulting in cell death. This 
internalization occurs via macropinocytosis and is mediated by the interaction of the ELP 
domain with cell surface heparan sulfate proteoglycans (HSPG). In this chapter, we further show 
that KGF-ELP selectively enhances macropinocytosis in high Keratinocyte Growth Factor 
Receptor (KGFR) expressing cancer cells. Finally, heterogeneous NPs comprising of KGF-ELP 
and (KLAKLAK)2-ELP selectively kill high KGFR expressing lung cancer cells with very little 
impact on normal cells. 
 Macropinocytosis is enhanced by several growth factors [30, 31]. Therefore, growth 
factors can be used to target high growth factor receptor expressing lung cancer cells [8, 32]. 
Indeed, our data demonstrate that macropinocytosis can be enhanced in KGFR over expressing 
cells using the KGF-ELP fusion protein. This led to an increase in (KLAKLAK)2-ELP 
internalization by KGF-ELP only in cells overexpressing the KGFR. This uncovers the 
opportunity to selectively deliver therapeutics using growth factor induced macropinocytosis. 
While non-targeted macropinocytosis has been described for the delivery of lytic peptides or NPs 
using cell penetration peptides [33], no studies describe the use of the keratinocyte growth factor 
to achieve targeted delivery through macropinocytosis. Macropinocytosis is beneficial over the 
commonly described receptor mediated internalization approaches that usually involve clathrin-
coated endocytosis. Firstly, macrop
efficient internalization of several nanoparticles in one macropinosome [31]. Since, 
macropinosomes are inherently leaky, it allows rapid release of the nanoparticles in the cytosol 
escaping lysosomal degradation [34]. Finally, receptor mediated endocytosis results in the 
formation of one vesicle per ligand/receptor whereas in macropinocytosis once one nanoparticle 
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binds to the receptor it will result in the uptake of several nanoparticles in the vicinity of the cells 
due to cell surface ruffling induced by the growth factor; thereby, increasing efficiency of 
uptake. It is to be noted that this process involves enhancing the process of macropinocytosis 
through growth factor signaling as opposed to blocking it, which is in contrast to previous 
approaches. Therefore, care needs to be taken in using this strategy, as there might be some 
unwanted cancer enhancing effect due to growth factor receptor signaling.  
 In summary, in this chapter we have taken advantage and expanded on the findings in the 
previous chapter. Previously we demonstrated that (KLAKLAK)2-ELP is internalized by cells 
through the process of macropinocytosis. Furthermore, the ELP domain also becomes critical 
since it facilitates the (KLAKLAK)2-ELP nanoparticles to be bound to the cell surface; a step 
that is required for macropinocytosis. Since macropinocytosis can be stimulated by growth 
factors; in this chapter, we selectively enhanced macropinocytosis and the uptake of 
(KLAKLAK)2-ELP in KGFR overexpressing lung cancer cells using the fusion KGF-ELP. 
While we have focused on the delivery of the mitochondriotoxic peptide (KLAKLAK)2, this 
approach can easily be expanded to other peptides, imaging agents, or drugs thereby having 
broad applications in cancer as well as intracellular drug delivery. 
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Figure 3.1 Representation of clathrin-independent and clathrin-dependent endocytosis [35]. 
Right figure represents clathrin-independent endocytosis while left represent clathrin-dependent 
endocytosis. 
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Figure 3.2 Representation of the KGF-ELP purification and self-assemble property. Top, 
representation of the KGF gene, ELP genes, and their translation to the fusion (KLAKLAK)2-
ELP. Bottom, illustration of the phase transition property of the fusion above and below its 
transition temperature (Tt). 
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Figure 3.3 Internalization of KGF-ELP as seen by TEM. HCC827 cells were treated for 24 Hrs. with 50 μM of KGF-ELP; they were 
then prepared and analyzed as described in the materials and methods section. The red arrows show the location of the KGF-ELP 
nanoparticle. 
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Figure 3.4 KGFR expression in lung cancer and normal cells. RT-PCR was used to determine the 
Keratinocyte growth factor receptor (KGFR) expression in different cell lines. Normal lung cells 
(SAEC), cancerous lung cells (H292, H1650, A549, HCC827, H23), and normal skin cells 
(fibroblast) were tested for KGFR expression level. Cells were cultured in 6 well plates; once 
they were about 90% confluent, their total RNA was extracted and cDNA was produced as 
described in the material section. The results were normalized to Primary Small Airway 
Epithelial cells (SAEC). 
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Figure 3.5 Representation of the heterogeneous nanoparticle comprising of KGF-ELP and 
(KLAKLAK)2-ELP.  
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Figure 3.6 Enhanced internalization of (KLAKLAK)2-ELP assisted by KGF-ELP in KGFR 
overexpressing cells. A549 cells were treated for 24 Hrs. with four different formulations to test 
for improved internalization due to KGF-ELP. Since nanoparticle formation, which also 
improves internalization, is dependent on concentration, equimolar treatments in the absence of 
KGF-ELP were also included. Labeled (KLAKLAK)2-ELP (10 μM) was used in all treatments. 
The analysis was carried out using flow cytometry. Trypan blue was used in the sample 
suspensions before analysis to prevent the inclusion of particles bound on the cell surface in the 
analysis. These experiments were repeated two times with triplicates. * indicates p < 0.05 when 
compared to (KLAKLAK)2-ELP (10μ). 
 
 57 
Figure 3.7 KGF-ELP does not improve internalization of (KLAKLAK)2-ELP in low KGFR 
expressing cells. Fibroblasts were treated with either labeled (KLAKLAK)2-ELP (10μ) or a 
combination of labeled (KLAKLAK)2-ELP (10μ) and KGF-ELP (10μ) as described above. The 
analysis was carried out as described above. These experiments were repeated two times with 
triplicates. * indicates p < 0.05 when compared to (KLAKLAK)2-ELP (10μ). 
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Figure 3.8 Dose-dependent enhancement of macropinosome formation in KGFR overexpressing cells. A549 cells were treated with 
varying concentrations of KGF-ELP (1 μM, 10 μM, and 50 μM). After 24 Hrs., dextran tetramethylrhodamine was added for 1 Hr. 
before analysis. Fluorescent picture were taken at 10x magnification. 
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Figure 3.9 Quantification of macropinosome formation in A549 cells after KGF-ELP treatment. 
A549 cells were serum starved for 24 Hrs. and then treated for 24 Hrs. with different 
concentration of KGF-ELP (1μM, 10μM or 50μM). After treatment, rhodamine-labeled dextran 
was added for 1 Hr. and cells were washed at least 5 times with ice cold PBS before analysis 
using flow cytometry. Treatments were normalized to the control (no treatment). These 
experiments were repeated two times with triplicates. * indicates p < 0.05 when compared to 
control (no treatment). 
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Figure 3.10 Quantification of macropinosome formation in fibroblast cells after KGF-ELP 
treatment. Fibroblasts were treated with 50μM of KGF-ELP following the steps described in 
figure 3.9; they were then analyzed by flow cytometry also following the aforementioned steps. 
These experiments were repeated two times with triplicates. * indicates p < 0.05 when compared 
to control (no treatment). 
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Figure 3.11 Cytotoxic effect of (KLAKLAK)2-ELP is higher in KGFR overexpressing cells 
when KGF-ELP is present. Fibroblasts, SAEC, H23, H292, A549, H1650 and HCC827 cells 
were serum starved for 24 Hrs. and then treated for 36 Hrs. with (KLAKLAK)2-ELP (10μM) 
combined with KGF-ELP (10μM). After treatment, cells were analyzed with a life/dead assay 
and quantified using image J. The treatments were normalized to their respective control (no 
treatment). These experiments were repeated two times with triplicates. * indicates p < 0.05 
when compared to control (no treatment). 
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CHAPTER 4: INHIBITION OF GLYCOLYSIS AS A POSSIBLE CANCER THERAPY 
 
4.1 Introduction 
 The enzyme phosphoglycerate mutase (PGM) has recently received much attention 
because it is the point at which glycolysis and anabolic biosynthesis are coordinated; this is done 
through the conversion of 3-phosphoglycerate (3PG) to 2-phosphoglycerate (2PG). PGM is 
activated by the phosphorylation of the histidine 11 (H11). In this chapter we show the synthesis 
of a fusion comprising of a peptide, KLVLIRHGESAW, derived from PGM and elastin like 
polypeptides (ELPs), PGM-ELP. The PGM domain in PGM-ELP comprises the H11 and a few 
more peptides from PGM; therefore, it acts as a competitive inhibitor for the phosphorylation of 
the PGM enzyme; the ELP domain will provide stability. Furthermore, we explore the cytotoxic 
effect of having multiple copies of the PGM peptide fused to ELP, (PGM)4-ELP, where the 
number indicates the number of PGM peptide copies in the fusion. 
4.2 Glycolysis and the Phosphoglycerate Mutase (PGM) Enzyme 
 One of the hallmarks of cancer is the uncontrolled proliferation and growth of cells. The 
formation of one cell is a very complex process that requires energy as well as the synthesis of 
macromolecules such as phospholipids, amino acids, and nucleic acids [1]. Energy in the form of 
ATP can be produced in two different areas of the cells and in the presence (aerobic) or not 
(anaerobic) of oxygen. ATP can be produced in the cytosol via glycolysis; this is very inefficient 
ATP producing pathway since it happens in the absence of oxygen; during glycolysis a net of 2 
ATP molecules are synthesized. ATP can also be synthesized within the mitochondria; this 
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process occurs in the presence of oxygen via oxidative phosphorylation; this process is called 
cell respiration. In the mitochondria, a net of 36 ATP molecules are obtained from a single 
molecule of glucose [2].  One could conclude that cancer cells, because of the high-energy 
requirements needed for proliferation, would favor aerobic respiration. However, several studies 
have consistently shown that the glycolytic rate in cancer cells is higher that in normal cells [3, 
4]; therefore, targeting glycolysis is an attractive alternative [5-7]. 
 Several studies have argued that higher ATP production is not likely the reason for high 
glycolytic rate; instead, they claimed that glycolysis provides the building blocks required for the 
synthesis of macromolecules (DNA, RNA, lipids, and proteins) needed for giving rise to new 
cells [8, 9]. Others maintained that glycolysis is responsible for faster ATP production needed for 
proliferating cells. Regardless of the conclusion of either of the arguments, it is clear that the 
inhibition of glycolysis can prove fruitful in the development of a targeted cancer therapy.  
 Glycolysis is a catabolic pathway through which a molecule of glucose is converted to 
two molecules of pyruvate through ten enzyme-catalyzed steps (Figure 4.1). Pyruvate is then 
taken into the mitochondria for energy production. During the different glycolytic steps, 
molecules that are the building block for macromolecules are synthetized. After glucose is 
internalized, it is phosphorylated forming glucose-6-phosphate (G6P). G6P participates in the 
pentose phosphate pathway that gives rise to nucleic acid synthesis. Glyceraldehyde-3-phosphate 
(G3P), an intermediate of glycolysis, participates in the synthesis of lipids. Also, the glycolytic 
intermediate 3-phosphoglycerate (3PG) contributes to the synthesis of amino acids.  
 Due to the involvement of glycolysis in biosynthesis, there are several possible targets in 
the glycolytic pathway that could result in proliferation and growth being halted [10-12]. Some 
of them are already being explored. For example, the compound 2-Deoxyglucose (2-DG) is a 
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glucose analog that reduces the phosphorylation of glucose by the enzyme hexokinase (HK) . 
HK does not distinguish between 2-DG and glucose; therefore, the phosphorylation of the analog 
by HK reduces the amount of phosphorylated glucose available for glycolysis [6, 13]. This 
blocks the pentose phosphate pathway resulting in the synthesis of ribose, precursor of nucleic 
acids, being halted. Furthermore, because 2-DG acts in the early steps of glycolysis, it also 
disrupt other anabolic reactions occurring downstream from the pentose phosphate pathway such 
as lipid and protein synthesis. Several studies have reported the positive results associate with 2-
DG when used alone [14] and in combination with other therapeutic agents [15, 16]; however, 
development of resistance has also being reported [17, 18]. Moreover, other studies have argued 
that the mechanism by which 2-DG inhibits cell growth need to be further studied since its 
mechanism of action is not fully understood [19].  
 Other groups have focus on the enzyme phosphoglycerate mutase (PGM) as a possible 
target to block glycolysis [20]. This enzyme is considered a useful target for cancer treatment 
because it is located at the branching point between glycolysis and anabolic biosynthesis [21-23], 
both required for cell growth and proliferation. In addition, PGM has been found to be 
overexpress in some cancers [24, 25]. This enzyme catalyzes the conversion of 3-
phosphoglycerate (3PG) to 2-phosphoglycerate (2PG). Inhibition of PGM will result in increase 
3PG and decrease 2PG, both of which have detrimental consequences for the cell. Accumulation 
of 3PG results in inhibition of the enzyme 6-phosphogluconate dehydrogenase (6PGD) [22]; this 
enzyme is part of the pentose phosphate pathway, which is responsible for the synthesis of 
nucleotide precursors. The reduction of 2PG reduces the activity of the enzyme 
phosphoglycerate dehydrogenase enzyme (PHGDH), preventing the synthesis of serine from 
3PG and further increasing the amount of 3PG. Furthermore, decrease in 2PG results in 
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reduction of phosphoenolpyruvate (PEP) and its conversion to pyruvate carried out by the 
enzyme pyruvate kinase (PK) isoform 2 (PKM2) which is stimulated by serine. In short, 
inhibiting this enzyme will have a dual effect; it will result in the reduction of ATP due to 
decrease in pyruvate synthesis (catabolic reaction) and inhibition of anabolic biosynthesis.  
 Previous work used a synthetic peptide (Leu-Ile-Arg-His-Gly-Glu or LIRHGE) derived 
from the PGM domain that included a histidine amino acid that is phosphorylated when PGM is 
in its active form [21]. This sequence was functionalized by the addition of a cell penetrating 
peptide (CPP) to increase its internalization. The results show a decrease in cell growth; 
however, the effect of the peptide dissipated after approximately three days and cancer cells 
continued proliferating. The study suggested that this could be due to degradation of the peptide.  
4.3 Fusion PGM-ELP  
4.3.1 Materials and Methods 
 Fetal bovine serum (FBS) and Dulbecco modified Eagle Medium (DMEM) were 
purchased from Life Technologies. The restriction enzymes and other enzymes used for cloning 
were purchased from New England Biolabs (Ipswich, MA). H292, A549, H1650, H23, and 
HCC827 cells were kindly donated by Dr. Haura from Moffit Cancer Center. CRCL2522, 
fibroblasts, were purchased from ATCC (Manassas, VA). Human Small Airway Epithelial Cells 
(SAEC) cells were kindly donated by Dr. Narasaiah Kolliputi from the Department of Internal 
Medicine at USF Health. The PGM gene was purchased from GenScript (Piscataway, NJ). The 
miniprep and gel extraction kits were purchased from QIAGEN. The reagents for RT-PCR were 
purchased from Bio-Rad. 
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4.3.1.1 Synthesis of PGM-ELP and (PGM)4-ELP 
 The PUC57 plasmids containing the genes (VPGVG)5 , (VPGVG)2VPGCG(VPGVG)2 ,  
and KLVLIRHGESAW (PGM sequence) were purchased from Genscript (Piscataway, NJ). The 
V40C2 encoding gene was made using recursive direction ligation method as described 
previously [26]. The PGM gene was excised using PflMI and Bgll enzymes. This gene was then 
run on a 0.08% agarose gel and extracted using QIAquick Gel Extraction Kit. The restriction 
enzyme PflMI linearized the pUC19 vector containing the ELP sequence and the excised PGM 
gene was cloned in frame with the ELP gene. This resulted in the pUC19 vector containing the 
PGM-ELP fusion protein gene flanked by pfIMI and BgII sites. The sequences encoding for the 
fusion protein was then removed from the pUC19 vector using pflMI and BgII enzymes and 
recovered by gel extraction as explained above. After extraction, this gene was cloned in a 
modified pET25b+ expression vector through SfiI site. This vector was modified to incorporate a 
SfiI cloning site for the cloning of the fusion protein. 
 The pET25b+ vector containing the fusion protein gene was transformed into BLRD 
competent cells through heat shock at 42oC. A starting culture of 50 ml was inoculated overnight 
and added to a 1 L culture the next day. The 1 L culture was then grown overnight and 
subsequently purified by inverse transition cycling as described previously [27]. Figure 4.2 
shows a representation of the genes for PGM and ELP and the production of the fusion PGM-
ELP. The fusion (PGM)4-ELP was synthesized as described above, but four copies of the PGM 
gene were cloned in frame with the ELP gene resulting in the fusion (PGM)4-ELP. 
4.3.1.2 Cell Culture  
 Cells were cultured in a humidified incubator at 370C and 5% CO2. Cells were seeded on 
24 or 48-well plates until they were approximately 70% confluent.  CRL-2522 (non-malignant 
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human foreskin fibroblast), A549 (human lung carcinoma), H292 (human lung carcinoma), 
HCC827 (human lung adenocarcinoma), H23 (human lung adenocarcinoma), and H1650 (human 
lung adenocarcinoma) were grown in DMEM supplemented with 10% FBS and 1% AA 
(Complete Medium). SAEC were cultured in airway epithelial cell basal medium (PCS-300-030) 
supplemented with Small Airway Epithelial Cell Growth Kit (PCS-301-040).  
4.3.1.3 Live/Dead Assay 
 Cells were seeded and treated only once for 1,2 ,or 6 days as indicated. The media was 
changed every two to three days but the treatment was not repeated. After their respective 
treatments, ethidium homodimer-1 (Life Technologies  cat # E1169) was added to each well to a 
final concentration of 4uM. Cells were then incubated for 1 hour at 37oC. After the incubation 
time, cells were washed twice with PBS to remove floating cells. NucBlue (Life Technologies 
R37605) was then added for 20 minutes to stain nuclei, followed by two washes with PBS. Eight 
random pictures were taken per well using the EVOS fluorescence microscope (10X 
magnification). Pictures were taken in different channels (blue, green, red) and overlay. 
Live/dead cell discrimination was performed using image J.  A macro was created using the 
functions split channel, threshold, and cell counter to count the total number of live cells (blue) 
in each picture. Dead cells that were not removed after the washes were stained red or magenta 
(blue and red); adjusting the threshold for the picture being analyzed easily isolated these cells. 
Therefore, the final count of cells per picture only included live cells.  
4.3.1.4 2-Phosphoglycerate (2PG) Assay 
 Cells (H292) were seeded in six-well plates (500,000/well). After 24 Hrs. they were 
treated for 48 Hrs. with either 10 μM or 100 μM of PGM-ELP. After treatment they were lysed 
following the assay protocol. The 2-phosphoglycerate colorimetric assay kit (BioVision cat # 
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k778-100) was used to measure the concentration of 2PG and the protocol was followed as 
described in the kit. 
4.3.1.5 Labeling of the Fusion Proteins 
 The cysteines present in the ELP sequence were labeled using maleimide chemistry for 
the particle internalization experiments. Fluorescein-5-maleimide (AnaSpec Inc cat # 81405) was 
mixed with the fusion proteins. The mixture was placed on an orbital shaker and incubated at 
room temperature for 2 hours. Unconjugated fluorescein was removed by a series of hot and cold 
cycles on a bench top centrifuge ran at a speed of 20000g for 10 minutes each time. The 
supernatant was discarded after the hot spin and an equal amount of cold sterile PBS was added. 
This mixture was spun at 4 0C and the supernatant was collected while the pellet was discarded. 
This formed one complete cycle of inverse temperature cycling. At least 5 cycles were 
performed to get rid of all the unconjugated Fluorescein. 
4.3.1.6 Fusion Protein Internalization Assay 
 Cells (50,000/well) were seeded in 24-well plates and cultured as described above. They 
were let grow until they were about 70% confluent and were treated with the indicated 
treatments. For analysis, cells were washed twice with ice-cold PBS and were trypsinized using 
0.25% trypsin (100 μl). Cells were pelleted and re-suspended in 300 μl of PBS containing 50 
-diamidino-2-
phenylindole (DAPI) to allow exclusion of nonviable cells. The cells were analyzed using flow 
cytometry and either the percent of fluorescent cells or the average intensity was quantified and 
reported.  
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4.3.1.7 Statistical Analysis 
 For statistical significance, the p value was calculated using ANOVA single factor. P 
values < 0.05 were considered significant. The reported errors indicate the ±SEM.  
4.3.2 Results 
4.3.2.1 The Fusion PGM-ELP Interferes with the Phosphoglycerate Mutase Enzyme 
 The glycolytic enzyme phosphoglycerate mutase (PGM) controls both the glycolytic 
pathway and the synthesis of macromolecules needed for cell growth and proliferation. Previous 
works showed that a using a peptide derived from the PGM domain could act as a competitive 
inhibitor for this enzyme and inhibit cell proliferation. However, this inhibition was transient and 
lasted for about 3 days; the study concluded this occurred because of the peptide degradation 
[21]. We reasoned that ELPs could increase stability of the peptide since previous works have 
shown that ELPs are resistant to degradation [28]. Therefore, we purified the fusion PGM-ELP 
and first tested for its bioactivity. Our results clearly show that the fusion PGM-ELP is bioactive 
and causes cell death at high concentration after 24 and 48 Hrs. (Figures 4.3, 4.4 and 4.5). 
Furthermore, since PGM-ELP competes with the phosphorylation of PGM (Figure 4.6), a 
decreased in PGM phosphorylation would result in the 2PG concentration decrease. Indeed, we 
found that treatments with PGM-ELP decreased the amount of 2PG (Figure 4.7) after 48 hours. 
Combined, these results suggest that PGM-ELP is bioactive and causes cell death by competing 
with an enzyme (PGM) in the glycolytic pathway. 
 We wanted to test the cytotoxicity of PGM-ELP in different cells lines. Therefore, lung 
cancer cells (A549, H23, HCC827, H292), connective tissue cells (Fibroblasts, Fb), and normal 
lung cells (Small airway epithelial cells, SAEC) were tested for PGM-ELP cytotoxicity. Cells 
were treated as describe in the material and methods section with 50 μM of PGM-ELP. After 6 
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days, PGM-ELP displays cytotoxic effects in all cell lines; however, its effect is noticeable 
higher in the lung cancer cells (Figure 4.8). Furthermore, to test if the ELP domain assisted in 
improving the killing effect of the PGM domain, cells were also treated with the PGM peptide 
(50 μM) and the results were compared to the PGM-ELP 50 μM treatment (Figure 4.9). The 
results clearly show that the fusion PGM-ELP is much more cytotoxic than the PGM peptide.  
4.3.2.2 The Internalization of PGM-ELP is Improved by KGF-ELP 
 We reasoned that the internalization and therefore cytotoxic effect of PGM-ELP could be 
enhanced if the endocytotic mechanism of macropinocytosis is stimulated. As described in 
chapter 3, the fusion KGF-ELP induces macropinocytosis in keratinocyte growth factor receptor 
(KGFR) overexpressing cells (A549); therefore, an heterogeneous nanoparticle comprising of 
PGM-ELP and KGF-ELP (Figure 4.10) could improve the internalization of PGM-ELP in A549 
cells. Indeed, our results clearly show that including KGF-ELP in the treatment resulted in an 
approximately 20 fold increase when compared to the PGM-ELP 10 μM treatment (Figure 4.11). 
However, since adding 5 μM of KGF-ELP changes the molarity of the treatment, we also 
included and 15 μM PGM-ELP treatment; this still shows more than a 2-fold increase when 
KGF-ELP is part of the treatment (Figure 4.11). In addition, the treatment consisting of 
unfunctionalized ELP and PGM-ELP shows no increased in PGM-ELP internalization when 
compared to the 15 μM PGM-ELP (Figure 4.11). Altogether, the data implies that KGF-ELP 
improves internalization of PGM-ELP.  
4.3.2.3 KGF-ELP Enhances the Cytotoxic Effect of PGM-ELP in KGFR Overexpressing 
Cells 
 Having found that KGF-ELP increases PGM-ELP internalization in A549 cells, we tested 
if this would translate to higher cytotoxicity in these cells. Cells were treated as described in the 
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material and methods section and a concentration of PGM-ELP that did not cause cytotoxicity 
after 3 days was used (50 μM). The results show clearly that after 6 days PGM-ELP is cytotoxic 
and about 55% of cells have died (Figure 4.12). Interestingly, the treatment that included the 
fusion KGF-ELP caused almost 95% of cell death (Figure 4.12). These results further confirmed 
that the inclusion of KGF-ELP improves internalization and cytotoxicity of PGM-ELP. 
 Cells with different levels of KGFR expression (chapter 3) were treated with the 
formulations PGM-ELP (50 μM) or PGM-ELP (50 μM) and KGF-ELP (20 μM). All cells, 
except A549, show no improvement by the inclusion of KGF-ELP in the treatment (Figure 4.13). 
A549, having the highest KGFR expression, shows a definite increase in cells death. Altogether, 
the results propose that the presence of KGF-ELP adds selectivity to the treatment. 
4.3.2.4 The Addition of Multiple PGM Domains to ELP Enhances Cytotoxicity 
 Having observed that PGM-ELP is cytotoxic, we reasoned that this effect could be 
boosted if multiple PGM domains are fused to ELP. To this end, we added four PGM domains to 
ELP, (PGM)4-ELP. We treated HCC827 cells, as described above, with varying concentrations 
of (PGM)4-ELP (10 μM, 50 μM, and 100 μM) for 3 days. Interestingly, all concentrations 
induced cell death (Figure 4.14) after this short period of time. Furthermore, Figure 4.15 clearly 
shows that the same treatment (50 μM) of (PGM)4-ELP and PGM-ELP induced approximately 
the same amount of cells death but (PGM)4-ELP only took 3 days compared to the 6 days 
needed for PGM-ELP.  
4.4 Discussion and Summary 
 The tumor microenvironment is very complex; a single tumor has cells with different 
genotypes; therefore, a single therapeutic might not be enough to prevent the tumor from 
growing. Many have looked into targeting glycolysis since higher than normal glycolytic rate has 
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been observed in cancer cells regardless of their genotype. Herein, we report the synthesis of the 
fusion protein PGM-ELP that inhibits glycolysis resulting in cell death. Furthermore, we show 
that the heterogeneous nanoparticle comprising of PGM-ELP and KGF-ELP enhances 
internalization and cytotoxic effect of PGM-ELP in KGFR overexpressing cells. Finally, a fusion 
consisting of multiple copies of the PGM domain fuse to ELP, (PGM)4-ELP, improves the 
fusion cytotoxic effect. 
 Previous works have demonstrated that using an amino acid sequence from the 
phosphoglycerate mutase enzyme (PGM) that encompasses the histidine 11 (H11) prevents cell 
proliferation. However, the promising observations are only temporary; the study suggested the 
degradation of the peptide as the cause. We synthesized the fusion PGM-ELP; the PGM domain 
in this fusion is derived from the PGM enzyme and encompasses H11. The ELP would provide 
stability by preventing degradation. Our results clearly show this fusion to be bioactive and 
causing cell death after three days but only at high concentrations (100 μM). Furthermore, the 
cytotoxic effect is also observed in various cell lines after 6 days, even at low concentrations (50 
μM). We believe this observation is because of the number of H11 sites available. The lower 
concentration offers less number of H11 sites; therefore, glycolytic inhibition takes longer. This 
could explain why a 50 μM treatment does not cause cell death after 3 days, but it does after 6 
days. In addition, since the cells were treated only once during the 6-day period, it is reasonable 
to conclude that the PGM-ELP was still present within the cells. Therefore, the ELP domain 
provided stability to the fusion. Moreover, the treatment with the PGM peptide was much less 
cytotoxic than the fusion PGM-ELP. We reasoned that this could be attributed to the stability 
imparted by the ELP domain as well as the interaction between the ELP domain and the cell 
surface. This interaction permits the PGM-ELP fusion to be bound to the cell surface; therefore, 
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allowing cells to have more access to the molecules compared to the unbound PGM peptide. Our 
data also demonstrates that the fusion PGM-ELP acts by affecting glycolysis; this can be 
concluded from the approximately 60% reduction in the concentration of 2PG in the treated 
cells. 2PG is the product of the PGM enzyme; therefore, a drastic reduction in its concentration 
can safely be attributed to an inhibited PGM enzyme. 
 Additionally, our data shows that not all cells responded equally to the PGM-ELP 
treatment. The most obvious difference is observed in groups, cancer cell group versus normal 
cell group. One reason why cancer cells responded better to the treatment can be attributed to 
their inherently more active nature; cancer cells exhibit higher levels of macropinocytosis 
compared to normal cells. Another plausible explanation is that cancer cells are highly dependent 
on glycolysis; therefore, inhibiting this pathway may have more impact in cancer than in normal 
cells. 
 Our results show that the addition of the KGF-ELP fusion to the treatment resulted in 
higher PGM-ELP uptake in KGFR overexpressing cells. Some of the internalization can be 
attributed to the higher concentration of the treatment that included KGF-ELP. However, when 
the same concentration treatments are compared, there still exist an increase in PGM-ELP uptake 
when KGF-ELP is part of the formulation. This can be associated to the enhancement of 
macropinocytosis due to the interaction between KGF-ELP and the KGFR as demonstrated in 
chapter 3.  Furthermore, the increase in internalization also resulted in improved cytotoxicity in 
cells overexpressing the KGFR. Our data clearly shows that KGFR overexpressing cells 
decreased by approximately 80% when compared to the formulation containing only PGM-ELP.  
 Previously, we hypothesized that the number H11 sites available may be the reason for 
the lower concentration treatment (50 μM) to take effect after 6 days; therefore, we synthesized a 
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fusion containing four H1 sites, (PGM)4-ELP. The results clearly display a dose dependent 
cytotoxic effect. Interestingly, the killing effect was observed after only 3 days. Comparing the 
HCC827 data for the 50 μM PGM-ELP treatment (6 days) and 50 μM (PGM)4-ELP treatment (3 
days) , it becomes very apparent the improvement in efficiency and cytotoxicity due to the higher 
number of H11 sites. The HCC827 6-day treatment resulted in an approximately 60% cell death 
while the 3-day treatment resulted in about 70% cell death. Therefore, our data validates the idea 
that increasing the number of H11 sites improves toxicity by PGM-ELP. 
 In summary, we have demonstrated that the fusion PGM-ELP induces cell death by 
inhibiting glycolysis. Furthermore, this fusion seems to have a higher effect in cancer cells, 
which could be related to their high dependence in glycolysis and/or their intrinsic more active 
nature. We also showed that the heterogeneous nanoparticle comprising of KGF-ELP and PGM-
ELP enhances the internalization and cytotoxic effect of PGM-ELP in KGFR overexpressing 
cells. Lastly, our data suggests a correlation between the number of H11 sites and the efficacy of 
the PGM-ELP; that is, (PGM)4-ELP is more efficient than PGM-ELP in terms of killing time 
and percent of killing. 
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Figure 4.1 Representation of the glycolytic pathway [29]. 
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Figure 4.2 Graphical representation of PGM-ELP synthesis and its self-assemble property. Top, 
representation of the PGM gene, ELP genes, and their translation to the fusion PGM-ELP. 
Bottom, illustration of the phase transition property of the fusion above and below its transition 
temperature (Tt). The fusion is soluble below its Tt and aggregates above its Tt. 
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Figure 4.3 Phase contrast picture of the PGM-ELP treatment. A549 cells were treated for 3 days; after which, phase contrast 
microscope pictures were taken. Top row show 4X magnification and bottom row 10X magnification, the columns show the different 
concentrations used (10 μM, 50 μM, and 100 μM). The control received no treatment. 
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Figure 4.4  Quantification of live cells after a 24 Hr. treatment with PGM-ELP. A549 were 
seeded and quantified as described in M&M. All the treatments have been normalized to the 
control. 
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Figure 4.5 Quantification of live cells after a 48 Hr. treatment with PGM-ELP. A549 were 
seeded and quantified as described in M&M. All the treatments have been normalized to the 
control. 
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Figure 4.6 Graphical representation of the intracellular effect of PGM-ELP on the glycolytic 
pathway. Briefly, the phosphorylating complex that activates the PGM enzyme will also 
phosphorylate the PGM-ELP fusion. This reduces the availability of activated PGM, which 
results in increase 3-PG and decrease 2-PG. Higher 3-PG concentration blocks 6PGD; therefore, 
glycolysis and macromolecule synthesis (Ribose-5-phosphate) are inhibited. 
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Figure 4.7 2PG intracellular concentration in H292 cells after PGM-ELP treatment. A 2PG 
colorimetric assay was used to show inhibition of the PGM enzyme. H292 cells were treated 
with PGM-ELP (10 μM and 100 μM) for 48 Hrs. After the treatment the concentration of 2PG 
was measured and normalized to the control (no treatment). 
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Figure 4.8 Quantification of live cells in various cell types after PGM-ELP treatment. Various cell lines (cancerous and non 
cancerous) were treated with 50 μM of PGM-ELP. The media was changed every two days after treatment and the cells were not 
retreated. Six days after treatment, the quantification was done as described in the M&M section.  
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Figure 4.9 PGM peptide and PGM-ELP treatments. Cells were treated with 50 μM of either 
PGM peptide or PGM-ELP for 6 days. The media was changed every two days, but the 
treatments were not repeated. Clearly, the data shows that PGM-ELP is more cytotoxic than the 
PGM peptide. Treatments were normalized to their respective PGM peptide treatment. 
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Figure 4.10 Graphical representation of the heterogeneous nanoparticle comprising of KGF-ELP 
and PGM-ELP. 
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Figure 4.11 Normalized internalization of PGM-ELP in the presence and absence of KGF-ELP. 
A549 cells were treated with the described formulations for 24 Hrs. All formulations consist of 
10 μM labeled PGM-ELP. The intensity relates to the amount of labeled PGM-ELP internalized 
per cell. The quantification was carried out by flow cytometry. * = p < 0.05. Number in paren-
thesis represent the concentration in μM. 
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Figure 4.12 KGF-ELP enhances the PGM-ELP cytotoxic effect in KGFR overexpressing cells. 
A549 were treated once and the media was changed every two days. Six days after treatment, the 
quantification was done as described in the M&M section; the results were normalized to the 
control (no treatment). * = p < 0.05.Number in parenthesis represent the concentration in μM. 
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Figure 4.13 KGF-ELP enhances PGM-ELP cytotoxicity only in KGFR overexpressing cells. Various cell lines (cancerous and non 
cancerous) were treated with 50 μM of PGM-ELP and 20 μM of KGF-ELP. The media was changed every two days after treatment 
and the cells were not retreated. Six days after treatment, the quantification was done as described in the M&M section. Results were 
normalized to the PGM-ELP treatment. 
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Figure 4.14 (PGM)4-ELP induces killing in a dose dependent manner. HCC827 cells were 
treated for 3 days with the (PGM)4-ELP fusion with the shown concentrations. The results were 
normalized to the control (no treatment). * = p < 0.05. 
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Figure 4.15 (PGM)4-ELP is more cytotoxic than PGM-ELP. HCC827 cells were treated with the 
same concentrations of (PGM)4-ELP and PGM-ELP for 3 and 6 days, respectively. The graph 
clearly shows approximately the same percent of live cells after treatment when each is 
compared to its respective control (no treatment).  
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CHAPTER 5: SUMMARY, CONCLUSIONS AND FUTURE WORK 
 
5.1 Summary and Conclusions 
 In this doctoral research, we have shown the selective enhancement of macropinocytosis 
for the treatment of lung cancer. This is a novel approach that takes advantage of an endocytotic 
mechanism that is inherently present in cancer cells, macropinocytosis. Macropinocytosis is 
transient and can be stimulated by the interaction between growth factors and their receptors on 
the cell surface. Herein, we used the keratinocyte growth factor receptor (KGFR) as the target for 
our treatment; this receptor has been reported to be overexpressed in lung cancer. We used the 
fusion comprising of the keratinocyte growth factor (KGF) and elastin like polypeptides (ELPs), 
KGF-ELP, previously synthesized in our lab to enhance macropinocytosis in KGFR 
overexpressing cells. After this selective enhancement, a mitochondriotoxic fusion peptide 
comprising of (KLAKLAK)2 and ELP, (KLAKLAK)2–ELP, was delivered causing 
mitochondrial depolarization and subsequent cell death.  Finally, we used a glycolytic inhibitory 
peptide and fuse it to ELPs, PGM-ELP. This peptide was also delivered selectively to KGFR 
overexpressing cells using the KGF-ELP fusion; this also resulted in selective killing.  
 In chapter 2, we found that the fusion (KLAKLAK)2-ELP is mitochondriotoxic without 
the need to be functionalized; the nanoparticle conformation provided by the ELP backbone was 
enough to cause the internalization and cytotoxicity of the fusion. Furthermore, cell death occurs 
via mitochondrial depolarization and swelling. We found that the mechanism of internalization 
of (KLAKLAK)2-ELP is macropinocytosis; we believe the interaction between the ELP domain 
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of the fusion and heparan sulfate on the cell membrane allows for the proximity required for 
macropinocytosis to act on the (KLAKLAK)2-ELP nanoparticles. 
 In chapter 3, we have taken advantage and expanded on the findings in the previous 
chapter. Previously we demonstrated that (KLAKLAK)2-ELP is internalized by cells through the 
process of macropinocytosis. Furthermore, the ELP domain also becomes critical since it 
facilitates the (KLAKLAK)2-ELP nanoparticles to be bound to the cell surface; a step that is 
required for macropinocytosis. Since macropinocytosis can be stimulated by growth factors; in 
this chapter, we selectively enhanced macropinocytosis and the uptake of (KLAKLAK)2-ELP in 
KGFR overexpressing lung cancer cells using the fusion KGF-ELP. While we have focused on 
the delivery of the mitochondriotoxic peptide (KLAKLAK)2, this approach can easily be 
expanded to other peptides, imaging agents, or drugs thereby having broad applications in cancer 
as well as intracellular drug delivery. 
 In chapter 4, we have demonstrated that the fusion PGM-ELP induces cell death by 
inhibiting glycolysis. Furthermore, this fusion seems to have a higher effect in cancer cells, 
which could be related to their high dependence in glycolysis and/or their intrinsic more active 
nature. We also showed that the heterogeneous nanoparticle comprising of KGF-ELP and PGM-
ELP enhances the internalization and cytotoxic effect of PGM-ELP in KGFR overexpressing 
cells. Lastly, our data suggests a correlation between the number of H11 sites and the efficacy of 
the PGM-ELP; that is, (PGM)4-ELP is more efficient than PGM-ELP in terms of killing time 
and percent of killing.  
5.2 Future Work 
 The work we presented in this dissertation shows an innovative approach for targeted 
therapy; therefore, we believe it lays the groundwork for its advancement. Furthermore, due to 
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the adaptability of this system, it can easily be expanded to treat other types of cancers that may 
overexpress different growth factor receptors than the one we targeted such as the epidermal 
growth factor receptor as it occurs in breast and pancreatic cancers. 
 In addition, we focused on the selective delivery of cytotoxic peptides that aimed at either 
the mitochondria or glycolysis. However, due to the simplicity of our system, it is possible the 
formation of multivalent nanoparticles that could selectively aim at multiple targets. For 
instance, instead of targeting either the mitochondria or glycolysis, a multivalent nanoparticle 
could disrupt the mitochondria while blocking glycolysis; this could have synergistic effects on 
the treatment of cancer. Moreover, this targeted system is not limited to the delivery of cytotoxic 
peptides. Due to the cysteine amino acid that forms part of our ELP construct, using simple 
maleimide chemistry allows the conjugation of cancer therapeutics that can be selectively 
delivered by macropinocytosis. This could result in improved intracellular concentration of the 
therapeutics, prevention of endosomal entrapment and lysosomal degradation.  
 Finally, the application of selectively stimulating macropinocytosis is not limited to the 
treatment of cancer. We believe that it can be further exploited in other fields such as in gene 
therapy. In this field, the targeted delivery of a gene is critical since unwanted gene insertion or 
inactivation may have severe consequences on the patient. Therefore, a selective delivery of the 
gene by macropinocytosis can ensure the therapy reaches its target and minimizes side effects. 
 Overall, we envision that further study of our work can result in improving current 
targeted treatments for cancer. Additionally, we see the possibility of expanding this research to 
other fields for which selective delivery is paramount. 
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Appendix A: List of Abbreviations 
(KLAKLAK)2  .......................KLAKLAKKLAKLAK 
2-DG ...................................... 2-Deoxyglucose 
2PG ........................................2-Phosphoglycerate 
3PG ........................................3-Phosphoglycerate 
6PGD......................................6-phosphogluconate dehydrogenase 
A .............................................Alanine 
A549 .......................................Adenocarcinoma cells, non-small cell lung cancer 
ATP ........................................Adenosine triphosphate 
CCCP .....................................Carbonylcyanide m- chlorophenylhydrazone 
CO2 .........................................Carbon dioxide 
Cyt c .......................................Cytochrome c 
DAPI ......................................4',6-diamidino-2-phenylindole 
DLS ........................................Dynamic light scattering 
DNA .......................................Dioxyribose nucleic acid 
E .............................................Glutamate 
EGF ........................................Epidermal growth factor 
EGFR .....................................Epidermal growth factor receptor 
ELP ........................................Elastin like polypeptide 
ETC ........................................Electron transport chain 
Fb ...........................................Fibroblast 
FBS ........................................Fetal bovine serum 
FITC .......................................Fluorescein isothiocyanate 
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G3P ........................................Glyceraldehyde-3-phosphate 
G6P ........................................Glucose-6-phosphate 
Gly..........................................Glycine 
H .............................................Histidine 
H11 .........................................Histadine at location 11  
H1650 .....................................Adenocarcinoma cells, non-small cell lung cancer 
H23 .........................................Adenocarcinoma cells, non-small cell lung cancer 
H292 .......................................Adenocarcinoma cells, non-small cell lung cancer 
HCC827 .................................Adenocarcinoma cells, non-small cell lung cancer 
HGF........................................Hepatocyte growth factor 
HK ..........................................Hexokinase 
HSPG .....................................Heparan sulfate proteoglycan 
I ..............................................Isoleucine 
ITC .........................................Inverse temperature cycling 
K .............................................Lysine 
KGF........................................Keratinocyte growth factor 
KGFR .....................................Keratinocyte growth factor receptor 
L .............................................Leucine 
LCST ......................................Lower critical solution temperature 
M&M .....................................Materials and methods 
mAb........................................Monoclonal antibodies 
MET .......................................MET proto-oncogene 
NSCLC ...................................Non-Small Cell Lung Cancer 
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O2 ...........................................Oxygen 
PBS ........................................Phosphate buffered-saline 
PEP .........................................phosphoenolpyruvate 
PGM .......................................Phosphoglycerate mutase 
PHGDH ..................................phosphoglycerate dehydrogenase enzyme 
PK ..........................................Pyruvate kinase 
PKM2 .....................................Pyruvate kinase isoform 2 
Pro ..........................................Proline 
R .............................................Arginine 
RME .......................................Receptor mediated endocytosis 
RNA .......................................Ribonucleic acid 
RT-PCR..................................Real-time polymerase chain reaction 
S .............................................Serine 
SAEC .....................................Small airway epithelial cells 
SEM .......................................Square error of the mean 
TEM .......................................Transmission electron microscopy 
TKI .........................................Tyrosine kinase inhibitor 
Tt ............................................Transition temperature 
Val ..........................................Valine 
W ............................................Tryptophan 
X .............................................Guest amino acid residue 
μM ..........................................Micromolar 
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